{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:36:22Z","timestamp":1789875382176,"version":"4.0.1"},"reference-count":425,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"MacKay Medical Hospital","award":["MMH-115-047"],"award-info":[{"award-number":["MMH-115-047"]}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"crossref","award":["114-2811-B-715-004"],"award-info":[{"award-number":["114-2811-B-715-004"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MacKay Medical University","award":["MMU-RD-112-2A-P003"],"award-info":[{"award-number":["MMU-RD-112-2A-P003"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2689287","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:33:50Z","timestamp":1782480830000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies"],"prefix":"10.1080","volume":"41","author":[{"given":"Wan-Jung","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Optometry, College of Medicine, MacKay Medical University","place":["New Taipei City, Taiwan"]},{"name":"Traditional Herbal Medicine Research Center, Taipei Medical University Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Ojha","sequence":"additional","affiliation":[{"name":"Department of Optometry, College of Medicine, MacKay Medical University","place":["New Taipei City, Taiwan"]},{"name":"Traditional Herbal Medicine Research Center, Taipei Medical University Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Rana","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Taipei Medical University","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Gautam","sequence":"additional","affiliation":[{"name":"SGT College of Pharmacy, SGT University","place":["Gurugram, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiun-Yi","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, MacKay Medical University","place":["New Taipei City, Taiwan"]},{"name":"Department of Surgery, MacKay Memorial Hospital","place":["Taipei, Taiwan"]},{"name":"Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-An","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Respiratory Therapy, College of Medicine, Taipei Medical University","place":["Taipei, Taiwan"]},{"name":"Division of Thoracic Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"13","key":"e_1_3_4_2_1","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3390\/cancers17132102","article-title":"Overcoming barriers in cancer biology research: current limitations and solutions","volume":"17","author":"Colonna G.","year":"2025","unstructured":"Colonna G. Overcoming barriers in cancer biology research: current limitations and solutions. Cancers (Basel). 2025;17(13):2102.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"e_1_3_4_3_1","doi-asserted-by":"crossref","first-page":"110699","DOI":"10.1016\/j.isci.2024.110699","article-title":"Modeling tumors as complex ecosystems","volume":"27","author":"Aguad\u00e9-Gorgori\u00f3 G","year":"2024","unstructured":"Aguad\u00e9-Gorgori\u00f3 G, Anderson AR, Sol\u00e9 R. Modeling tumors as complex ecosystems. iScience. 2024;27(9):110699.","journal-title":"iScience"},{"issue":"7","key":"e_1_3_4_4_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/cells14070488","article-title":"The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis","volume":"14","author":"Nishida A","year":"2025","unstructured":"Nishida A, Andoh A. The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis. Cells. 2025;14(7):488.","journal-title":"Cells"},{"issue":"6","key":"e_1_3_4_5_1","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen L","year":"2018","unstructured":"Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204\u20137218.","journal-title":"Oncotarget"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","first-page":"115015","DOI":"10.1016\/j.biopha.2023.115015","article-title":"Evaluation of the association of chronic inflammation and cancer: insights and implications","volume":"164","author":"Nigam M","year":"2023","unstructured":"Nigam M, Mishra AP, Deb VK, Dimri DB, Tiwari V, Bungau SG, Bungau AF, Radu A-F. Evaluation of the association of chronic inflammation and cancer: insights and implications. Biomed Pharmacother. 2023;164:115015.","journal-title":"Biomed Pharmacother"},{"issue":"7203","key":"e_1_3_4_7_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov R.","year":"2008","unstructured":"Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428\u2013435.","journal-title":"Nature"},{"issue":"5","key":"e_1_3_4_8_1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1096\/fj.11-0502ufm","article-title":"The resolution of inflammation: the devil in the flask and in the details","volume":"25","author":"Serhan CN.","year":"2011","unstructured":"Serhan CN. The resolution of inflammation: the devil in the flask and in the details. FASEB J. 2011;25(5):1441\u20131448.","journal-title":"FASEB J"},{"issue":"11","key":"e_1_3_4_9_1","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.3390\/molecules28114413","article-title":"Chronic inflammation\u2019s transformation to cancer: a nanotherapeutic paradigm","volume":"28","author":"Sohrab SS","year":"2023","unstructured":"Sohrab SS, Raj R, Nagar A, Hawthorne S, Paiva-Santos AC, Kamal MA, El-Daly MM, Azhar EI, Sharma A. Chronic inflammation\u2019s transformation to cancer: a nanotherapeutic paradigm. Molecules. 2023;28(11):4413.","journal-title":"Molecules"},{"issue":"2","key":"e_1_3_4_10_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41416-022-01775-w","article-title":"Cancer-inducing niche: the force of chronic inflammation","volume":"127","author":"Afify SM","year":"2022","unstructured":"Afify SM, Hassan G, Seno A, Seno M. Cancer-inducing niche: the force of chronic inflammation. Br J Cancer. 2022;127(2):193\u2013201.","journal-title":"Br J Cancer"},{"key":"e_1_3_4_11_1","doi-asserted-by":"crossref","first-page":"117955492412346","DOI":"10.1177\/11795549241234637","article-title":"Helicobacter pylori and gastrointestinal cancers: recent advances and controversies","volume":"18","author":"Zhang C","year":"2024","unstructured":"Zhang C, Chen Y, Long Y, Zheng H, Jing J, Pan W. Helicobacter pylori and gastrointestinal cancers: recent advances and controversies. Clin Med Insights Oncol. 2024;18:11795549241234637.","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"e_1_3_4_12_1","first-page":"77","article-title":"Patients with malignant or pre-malignant cervical lesion have increased risk of becoming hepatitis B carrier","volume":"26","author":"Siu S","year":"2007","unstructured":"Siu S, Cheung T, Chan P, Lin C, Lo K. Patients with malignant or pre-malignant cervical lesion have increased risk of becoming hepatitis B carrier. J Exp Clin Cancer Res. 2007;26(1):77\u201381.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"e_1_3_4_13_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13027-022-00466-8","article-title":"Hepatitis B or C viral infection and the risk of cervical cancer","volume":"17","author":"Luo C","year":"2022","unstructured":"Luo C, Yu S, Zhang J, Wu X, Dou Z, Li Z, Yang E, Zhang L. Hepatitis B or C viral infection and the risk of cervical cancer. Infect Agent Cancer. 2022;17(1):54.","journal-title":"Infect Agent Cancer"},{"issue":"3","key":"e_1_3_4_14_1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser KE","year":"2023","unstructured":"De Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"6","key":"e_1_3_4_15_1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2010.02.029","article-title":"Nonresolving inflammation","volume":"140","author":"Nathan C","year":"2010","unstructured":"Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871\u2013882.","journal-title":"Cell"},{"issue":"6","key":"e_1_3_4_16_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov SI","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883\u2013899.","journal-title":"Cell"},{"issue":"6917","key":"e_1_3_4_17_1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens LM","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860\u2013867.","journal-title":"Nature"},{"key":"e_1_3_4_18_1","doi-asserted-by":"crossref","DOI":"10.5962\/bhl.title.32770","volume-title":"Cellular pathology as based upon physiological and pathological histology","author":"Virchow R.","year":"1863","unstructured":"Virchow R. Cellular pathology as based upon physiological and pathological histology. Philadelphia: JB Lippincott; 1863."},{"issue":"2","key":"e_1_3_4_19_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/cas.12333","article-title":"Gist of Dr. Katsusaburo Yamagiwa\u2019s papers entitled \u201cExperimental study on the pathogenesis of epithelial tumors\u201d(I to VI reports)","volume":"105","author":"Fujiki H.","year":"2014","unstructured":"Fujiki H. Gist of Dr. Katsusaburo Yamagiwa\u2019s papers entitled \u201cExperimental study on the pathogenesis of epithelial tumors\u201d(I to VI reports). Cancer Sci. 2014;105(2):143\u2013149.","journal-title":"Cancer Sci"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0065-230X(10)06004-5","article-title":"Genetically engineered mouse models in cancer research","volume":"106","author":"Walrath JC","year":"2010","unstructured":"Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. Genetically engineered mouse models in cancer research. Adv Cancer Res. 2010;106:113\u2013164.","journal-title":"Adv Cancer Res"},{"issue":"7994","key":"e_1_3_4_21_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui A","year":"2024","unstructured":"Cui A, Huang T, Li S, Ma A, P\u00e9rez JL, Sander C, Keskin DB, Wu CJ, Fraenkel E, Hacohen N. Dictionary of immune responses to cytokines at single-cell resolution. Nature. 2024;625(7994):377\u2013384.","journal-title":"Nature"},{"key":"e_1_3_4_22_1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3332\/ecancer.2017.721","article-title":"Dual role of inflammatory mediators in cancer","volume":"11","author":"Shrihari T.","year":"2017","unstructured":"Shrihari T. Dual role of inflammatory mediators in cancer. Ecancermedicalscience. 2017;11:721.","journal-title":"Ecancermedicalscience"},{"issue":"6917","key":"e_1_3_4_23_1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature01320","article-title":"Points of control in inflammation","volume":"420","author":"Nathan C.","year":"2002","unstructured":"Nathan C. Points of control in inflammation. Nature. 2002;420(6917):846\u2013852.","journal-title":"Nature"},{"key":"e_1_3_4_24_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases \u2013 elimination, equilibrium and escape","volume":"27","author":"Mittal D","year":"2014","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases \u2013 elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16\u201325.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcancer.2004.06.006","article-title":"Inflammation as a tumor promoter in cancer induction","volume":"14","author":"Philip M","year":"2004","unstructured":"Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14(6):433\u2013439.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"e_1_3_4_26_1","first-page":"149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron G","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014(1):149185\u2013149119.","journal-title":"J Immunol Res"},{"issue":"1","key":"e_1_3_4_27_1","first-page":"536761","article-title":"How do cytokines trigger genomic instability?","volume":"2012","author":"Aivaliotis IL","year":"2012","unstructured":"Aivaliotis IL, Pateras IS, Papaioannou M, Glytsou C, Kontzoglou K, Johnson EO, Zoumpourlis V. How do cytokines trigger genomic instability? Biomed Res Int. 2012;2012(1):536761.","journal-title":"Biomed Res Int"},{"issue":"2","key":"e_1_3_4_28_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani A","year":"2010","unstructured":"Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231\u2013237.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"e_1_3_4_29_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh N","year":"2019","unstructured":"Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121\u2013126.","journal-title":"Ann Afr Med"},{"key":"e_1_3_4_30_1","doi-asserted-by":"crossref","first-page":"122390","DOI":"10.1016\/j.lfs.2023.122390","article-title":"Chronic inflammation and cancer; the two sides of a coin","volume":"338","author":"Fernandes Q","year":"2024","unstructured":"Fernandes Q, Inchakalody VP, Bedhiafi T, Mestiri S, Taib N, Uddin S, Merhi M, Dermime S. Chronic inflammation and cancer; the two sides of a coin. Life Sci. 2024;338:122390.","journal-title":"Life Sci"},{"issue":"1","key":"e_1_3_4_31_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao H","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"e_1_3_4_32_1","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.freeradbiomed.2012.02.035","article-title":"Emerging avenues linking inflammation and cancer","volume":"52","author":"Kundu JK","year":"2012","unstructured":"Kundu JK, Surh Y-J. Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52(9):2013\u20132037.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"e_1_3_4_33_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten FR","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341.","journal-title":"Immunity"},{"issue":"1","key":"e_1_3_4_34_1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","article-title":"Insights gained from single-cell analysis of immune cells in the tumor microenvironment","volume":"39","author":"Ren X","year":"2021","unstructured":"Ren X, Zhang L, Zhang Y, Li Z, Siemers N, Zhang Z. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. Annu Rev Immunol. 2021;39(1):583\u2013609.","journal-title":"Annu Rev Immunol"},{"issue":"50","key":"e_1_3_4_35_1","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1038\/s41388-021-02054-3","article-title":"Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma","volume":"40","author":"Bischoff P","year":"2021","unstructured":"Bischoff P, Trinks A, Obermayer B, Pett JP, Wiederspahn J, Uhlitz F, Liang X, Lehmann A, Jurmeister P, Elsner A, et al. Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma. Oncogene. 2021;40(50):6748\u20136758.","journal-title":"Oncogene"},{"issue":"2","key":"e_1_3_4_36_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/biom13020344","article-title":"The application of single-cell RNA sequencing in the inflammatory tumor microenvironment","volume":"13","author":"Zhao J","year":"2023","unstructured":"Zhao J, Shi Y, Cao G. The application of single-cell RNA sequencing in the inflammatory tumor microenvironment. Biomolecules. 2023;13(2):344.","journal-title":"Biomolecules"},{"key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"1255727","DOI":"10.3389\/fphar.2023.1255727","article-title":"Trinity of inflammation, innate immune cells and cross-talk of signalling pathways in tumour microenvironment","volume":"14","author":"Attiq A","year":"2023","unstructured":"Attiq A, Afzal S. Trinity of inflammation, innate immune cells and cross-talk of signalling pathways in tumour microenvironment. Front Pharmacol. 2023;14:1255727.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"102673","DOI":"10.1016\/j.dnarep.2019.102673","article-title":"Inflammation-induced DNA damage, mutations and cancer","volume":"83","author":"Kay J","year":"2019","unstructured":"Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair (Amst). 2019;83:102673.","journal-title":"DNA Repair (Amst)"},{"issue":"11","key":"e_1_3_4_39_1","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/ijc.23192","article-title":"Chronic inflammation and oxidative stress in human carcinogenesis","volume":"121","author":"Federico A","year":"2007","unstructured":"Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121(11):2381\u20132386.","journal-title":"Int J Cancer"},{"issue":"2","key":"e_1_3_4_40_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1078-0432.CCR-08-0149","article-title":"Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe","volume":"15","author":"Aggarwal BB","year":"2009","unstructured":"Aggarwal BB, Vijayalekshmi R, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425\u2013430.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"e_1_3_4_41_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","article-title":"Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer","volume":"21","author":"Grivennikov SI","year":"2010","unstructured":"Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21(1):11\u201319.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8060","key":"e_1_3_4_42_1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity","volume":"640","author":"Yang J","year":"2025","unstructured":"Yang J, Yamashita-Kanemaru Y, Morris BI, Contursi A, Trajkovski D, Xu J, Patrascan I, Benson J, Evans AC, Conti AG, et al. Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity. Nature. 2025;640(8060):1052\u20131061.","journal-title":"Nature"},{"issue":"5","key":"e_1_3_4_43_1","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1172\/JCI121985","article-title":"Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1\/thromboxane A 2","volume":"129","author":"Lucotti S","year":"2019","unstructured":"Lucotti S, Cerutti C, Soyer M, Gil-Bernab\u00e9 AM, Gomes AL, Allen PD, Smart S, Markelc B, Watson K, Armstrong PC, et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1\/thromboxane A 2. J Clin Invest. 2019;129(5):1845\u20131862.","journal-title":"J Clin Invest"},{"issue":"7","key":"e_1_3_4_44_1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/1878-0261.12095","article-title":"EMT and inflammation: inseparable actors of cancer progression","volume":"11","author":"Suarez-Carmona M","year":"2017","unstructured":"Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 2017;11(7):805\u2013823.","journal-title":"Mol Oncol"},{"issue":"5","key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/0008-5472.CAN-11-3123","article-title":"Epithelial\u2013mesenchymal transition induced by TNF-\u03b1 requires NF-\u03baB\u2013mediated transcriptional upregulation of Twist1","volume":"72","author":"Li C-W","year":"2012","unstructured":"Li C-W, Xia W, Huo L, Lim S-O, Wu Y, Hsu JL, Chao C-H, Yamaguchi H, Yang N-K, Ding Q, et al. Epithelial\u2013mesenchymal transition induced by TNF-\u03b1 requires NF-\u03baB\u2013mediated transcriptional upregulation of Twist1. Cancer Res. 2012;72(5):1290\u20131300.","journal-title":"Cancer Res"},{"issue":"5","key":"e_1_3_4_46_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ccr.2009.03.016","article-title":"Stabilization of snail by NF-\u03baB is required for inflammation-induced cell migration and invasion","volume":"15","author":"Wu Y","year":"2009","unstructured":"Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-\u03baB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15(5):416\u2013428.","journal-title":"Cancer Cell"},{"issue":"25","key":"e_1_3_4_47_1","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/onc.2013.272","article-title":"Inflammatory chemokines and metastasis \u2013 tracing the accessory","volume":"33","author":"Borsig L","year":"2014","unstructured":"Borsig L, Wolf MJ, Roblek M, Lorentzen A, Heikenwalder M. Inflammatory chemokines and metastasis \u2013 tracing the accessory. Oncogene. 2014;33(25):3217\u20133224.","journal-title":"Oncogene"},{"issue":"15","key":"e_1_3_4_48_1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jama.2026.1114","article-title":"Obesity and cancer: a translational science review","volume":"335","author":"Shen S","year":"2026","unstructured":"Shen S, Brown KA, Green AK, Iyengar NM. Obesity and cancer: a translational science review. JAMA. 2026;335(15):1341\u20131350.","journal-title":"JAMA"},{"issue":"572","key":"e_1_3_4_49_1","doi-asserted-by":"crossref","first-page":"eabb5817","DOI":"10.1126\/scitranslmed.abb5817","article-title":"Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils","volume":"12","author":"Perego M","year":"2020","unstructured":"Perego M, Tyurin VA, Tyurina YY, Yellets J, Nacarelli T, Lin C, Nefedova Y, Kossenkov A, Liu Q, Sreedhar S, et al. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci Transl Med. 2020;12(572):eabb5817.","journal-title":"Sci Transl Med"},{"issue":"19","key":"e_1_3_4_50_1","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-10-2743","article-title":"Regulation of cancer stem cells by cytokine networks: attacking cancer\u2019s inflammatory roots","volume":"17","author":"Korkaya H","year":"2011","unstructured":"Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer\u2019s inflammatory roots. Clin Cancer Res. 2011;17(19):6125\u20136129.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"e_1_3_4_51_1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.trecan.2023.01.007","article-title":"From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts","volume":"9","author":"Arpinati L","year":"2023","unstructured":"Arpinati L, Scherz-Shouval R. From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts. Trends Cancer. 2023;9(5):421\u2013443.","journal-title":"Trends Cancer"},{"issue":"11","key":"e_1_3_4_52_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/intimm\/dxac013","article-title":"A variety of \u2018exhausted\u2019T cells in the tumor microenvironment","volume":"34","author":"Nagasaki J","year":"2022","unstructured":"Nagasaki J, Togashi Y. A variety of \u2018exhausted\u2019T cells in the tumor microenvironment. Int Immunol. 2022;34(11):563\u2013570.","journal-title":"Int Immunol"},{"issue":"2","key":"e_1_3_4_53_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41577-025-01221-x","article-title":"Regulators of CD8+ T cell exhaustion","volume":"26","author":"Sun Q","year":"2026","unstructured":"Sun Q, Dong C. Regulators of CD8+ T cell exhaustion. Nat Rev Immunol. 2026;26(2):129\u2013151.","journal-title":"Nat Rev Immunol"},{"key":"e_1_3_4_54_1","doi-asserted-by":"crossref","first-page":"1571212","DOI":"10.3389\/fimmu.2025.1571212","article-title":"Regulation of immunogenic cell death and potential applications in cancer therapy","volume":"16","author":"Fang K","year":"2025","unstructured":"Fang K, Yuan S, Zhang X, Zhang J, Sun S-l, Li X. Regulation of immunogenic cell death and potential applications in cancer therapy. Front Immunol. 2025;16:1571212.","journal-title":"Front Immunol"},{"issue":"12","key":"e_1_3_4_55_1","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed A","year":"2020","unstructured":"Ahmed A, Tait SW. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14(12):2994\u20133006.","journal-title":"Mol Oncol"},{"issue":"1","key":"e_1_3_4_56_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s43556-025-00248-9","article-title":"Tumor microbiome: roles in tumor initiation, progression, and therapy","volume":"6","author":"Zhang S","year":"2025","unstructured":"Zhang S, Huang J, Jiang Z, Tong H, Ma X, Liu Y. Tumor microbiome: roles in tumor initiation, progression, and therapy. Mol Biomed. 2025;6(1):9.","journal-title":"Mol Biomed"},{"issue":"2","key":"e_1_3_4_57_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping NE","year":"2021","unstructured":"Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta R, Wang Y, Wang Y, DePeaux K, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205\u2013215.","journal-title":"Nat Immunol"},{"key":"e_1_3_4_58_1","doi-asserted-by":"crossref","first-page":"217601","DOI":"10.1016\/j.canlet.2025.217601","article-title":"Advancing glioblastoma therapy: learning from the past and innovations for the future","volume":"617","author":"Rana M","year":"2025","unstructured":"Rana M, Liou K-C, Thakur A, Nepali K, Liou J-P. Advancing glioblastoma therapy: learning from the past and innovations for the future. Cancer Lett. 2025;617:217601.","journal-title":"Cancer Lett"},{"issue":"9","key":"e_1_3_4_59_1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.it.2022.07.004","article-title":"NF-\u03baB: blending metabolism, immunity, and inflammation","volume":"43","author":"Capece D","year":"2022","unstructured":"Capece D, Verzella D, Flati I, Arboretto P, Cornice J, Franzoso G. NF-\u03baB: blending metabolism, immunity, and inflammation. Trends Immunol. 2022;43(9):757\u2013775.","journal-title":"Trends Immunol"},{"issue":"1","key":"e_1_3_4_60_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-020-00936-9","article-title":"Crosstalks between inflammasome and autophagy in cancer","volume":"13","author":"Chung C","year":"2020","unstructured":"Chung C, Seo W, Silwal P, Jo E-K. Crosstalks between inflammasome and autophagy in cancer. J Hematol Oncol. 2020;13(1):100.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"e_1_3_4_61_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-\u03baB pathway in immunity and inflammation","volume":"17","author":"Sun S-C.","year":"2017","unstructured":"Sun S-C. The non-canonical NF-\u03baB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545\u2013558.","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"e_1_3_4_62_1","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1093\/emboj\/cdg534","article-title":"Genetic analysis of NF-\u03baB\/Rel transcription factors defines functional specificities","volume":"22","author":"Hoffmann A","year":"2003","unstructured":"Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-\u03baB\/Rel transcription factors defines functional specificities. EMBO J. 2003;22(20):5530\u20135539.","journal-title":"EMBO J"},{"issue":"1","key":"e_1_3_4_63_1","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu T","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun S-C. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2(1):17023\u201317023.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"e_1_3_4_64_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","article-title":"Regulation and function of NF-\u03baB transcription factors in the immune system","volume":"27","author":"Vallabhapurapu S","year":"2009","unstructured":"Vallabhapurapu S, Karin M. Regulation and function of NF-\u03baB transcription factors in the immune system. Annu Rev Immunol. 2009;27(1):693\u2013733.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"e_1_3_4_65_1","doi-asserted-by":"crossref","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-\u03baB pathway in inflammation","volume":"1","author":"Lawrence T.","year":"2009","unstructured":"Lawrence T. The nuclear factor NF-\u03baB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651\u2013a001651.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"e_1_3_4_66_1","first-page":"776","article-title":"New insights into NF-\u03baB signaling in innate immunity: focus on immunometabolic crosstalks","volume":"12","author":"Iacobazzi D","year":"2023","unstructured":"Iacobazzi D, Convertini P, Todisco S, Santarsiero A, Iacobazzi V, Infantino V. New insights into NF-\u03baB signaling in innate immunity: focus on immunometabolic crosstalks. Biology (Basel). 2023;12(6):776.","journal-title":"Biology (Basel)"},{"issue":"1","key":"e_1_3_4_67_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cr.2010.177","article-title":"Non-canonical NF-\u03baB signaling pathway","volume":"21","author":"Sun S-C.","year":"2011","unstructured":"Sun S-C. Non-canonical NF-\u03baB signaling pathway. Cell Res. 2011;21(1):71\u201385.","journal-title":"Cell Res"},{"issue":"2","key":"e_1_3_4_68_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1097-2765(01)00187-3","article-title":"NF-\u03baB-inducing kinase regulates the processing of NF-\u03baB2 p100","volume":"7","author":"Xiao G","year":"2001","unstructured":"Xiao G, Harhaj EW, Sun S-C. NF-\u03baB-inducing kinase regulates the processing of NF-\u03baB2 p100. Mol. Cell. 2001;7(2):401\u2013409.","journal-title":"Mol. Cell"},{"issue":"9","key":"e_1_3_4_69_1","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/biomedicines10092233","article-title":"The NF-\u03baB pharmacopeia: novel strategies to subdue an intractable target","volume":"10","author":"Verzella D","year":"2022","unstructured":"Verzella D, Cornice J, Arboretto P, Vecchiotti D, Di Vito Nolfi M, Capece D, Zazzeroni F, Franzoso G. The NF-\u03baB pharmacopeia: novel strategies to subdue an intractable target. Biomedicines. 2022;10(9):2233.","journal-title":"Biomedicines"},{"issue":"2","key":"e_1_3_4_70_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2006.12.033","article-title":"A fourth I\u03baB protein within the NF-\u03baB signaling module","volume":"128","author":"Basak S","year":"2007","unstructured":"Basak S, Kim H, Kearns JD, Tergaonkar V, O\u2019Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, et al. A fourth I\u03baB protein within the NF-\u03baB signaling module. Cell. 2007;128(2):369\u2013381.","journal-title":"Cell"},{"issue":"3","key":"e_1_3_4_71_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.gendis.2020.06.005","article-title":"The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases","volume":"8","author":"Zinatizadeh MR","year":"2021","unstructured":"Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi PK, Jalali SA, Miri SR. The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis. 2021;8(3):287\u2013297.","journal-title":"Genes Dis"},{"key":"e_1_3_4_72_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fonc.2018.00104","article-title":"Classical NF-\u03baB metabolically reprograms sarcoma cells through regulation of hexokinase 2","volume":"8","author":"Londhe P","year":"2018","unstructured":"Londhe P, Yu PY, Ijiri Y, Ladner KJ, Fenger JM, London C, Houghton PJ, Guttridge DC. Classical NF-\u03baB metabolically reprograms sarcoma cells through regulation of hexokinase 2. Front Oncol. 2018;8:104.","journal-title":"Front Oncol"},{"issue":"4","key":"e_1_3_4_73_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.22205\/sijbs\/2016\/v2\/i4\/103443","article-title":"Function of nuclear factor kappa B (NF-kB) in human diseases-a review","volume":"2","author":"Serasanambati M","year":"2016","unstructured":"Serasanambati M, Chilakapati SR. Function of nuclear factor kappa B (NF-kB) in human diseases-a review. SIJBS. 2016;2(4):368\u2013387.","journal-title":"SIJBS"},{"issue":"11","key":"e_1_3_4_74_1","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/ph18111764","article-title":"Targeting the NF-\u03baB pathway in cancer: mechanisms, resistance, and therapeutic potential across tumor types","volume":"18","author":"Lukas K","year":"2025","unstructured":"Lukas K, Nguyen J, Necas C, Dave K, Venketaraman V. Targeting the NF-\u03baB pathway in cancer: mechanisms, resistance, and therapeutic potential across tumor types. Pharmaceuticals. 2025;18(11):1764.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"e_1_3_4_75_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cells5020016","article-title":"The NF-\u03baB pathway and cancer stem cells","volume":"5","author":"Rinkenbaugh AL","year":"2016","unstructured":"Rinkenbaugh AL, Baldwin AS. The NF-\u03baB pathway and cancer stem cells. Cells. 2016;5(2):16.","journal-title":"Cells"},{"key":"e_1_3_4_76_1","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2147\/OTT.S161109","article-title":"Role of the NF\u03baB-signaling pathway in cancer","volume":"11","author":"Xia L","year":"2018","unstructured":"Xia L, Tan S, Zhou Y, Lin J, Wang H, Oyang L, Tian Y, Liu L, Su M, Wang H, et al. Role of the NF\u03baB-signaling pathway in cancer. Onco Targets Ther. 2018;11:2063\u20132073.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"e_1_3_4_77_1","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/biomedicines10061250","article-title":"NF-\u03baB: a double-edged sword controlling inflammation","volume":"10","author":"Liu D","year":"2022","unstructured":"Liu D, Zhong Z, Karin M. NF-\u03baB: a double-edged sword controlling inflammation. Biomedicines. 2022;10(6):1250.","journal-title":"Biomedicines"},{"issue":"1","key":"e_1_3_4_78_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imr.12908","article-title":"Therapeutic modulation of inflammasome pathways","volume":"297","author":"Chauhan D","year":"2020","unstructured":"Chauhan D, Vande Walle L, Lamkanfi M. Therapeutic modulation of inflammasome pathways. Immunol Rev. 2020;297(1):123\u2013138.","journal-title":"Immunol Rev"},{"issue":"4","key":"e_1_3_4_79_1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/mco2.104","article-title":"NF-\u03baB signaling in inflammation and cancer","volume":"2","author":"Zhang T","year":"2021","unstructured":"Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-\u03baB signaling in inflammation and cancer. MedComm. 2021;2(4):618\u2013653.","journal-title":"MedComm"},{"key":"e_1_3_4_80_1","doi-asserted-by":"crossref","first-page":"101042","DOI":"10.1016\/j.drup.2023.101042","article-title":"Inhibition of NF-\u03baB signaling unveils novel strategies to overcome drug resistance in cancers","volume":"73","author":"Li Y","year":"2024","unstructured":"Li Y, Zhao B, Peng J, Tang H, Wang S, Peng S, Ye F, Wang J, Ouyang K, Li J, et al. Inhibition of NF-\u03baB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resist Updat. 2024;73:101042.","journal-title":"Drug Resist Updat"},{"issue":"21","key":"e_1_3_4_81_1","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.3390\/cancers14215215","article-title":"Inhibition of I\u03baB kinase is a potential therapeutic strategy to circumvent resistance to epidermal growth factor receptor inhibition in triple-negative breast cancer cells","volume":"14","author":"Yi YW","year":"2022","unstructured":"Yi YW, You KS, Han S, Ha IJ, Park J-S, Lee S-G, Seong Y-S. Inhibition of I\u03baB kinase is a potential therapeutic strategy to circumvent resistance to epidermal growth factor receptor inhibition in triple-negative breast cancer cells. Cancers (Basel). 2022;14(21):5215.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"e_1_3_4_82_1","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41417-024-00828-x","article-title":"NF-\u03baB-activated oncogene inhibition strategy for cancer gene therapy","volume":"31","author":"Dai W","year":"2024","unstructured":"Dai W, Wu J, Shui Y, Wu Q, Wang J, Xia X. NF-\u03baB-activated oncogene inhibition strategy for cancer gene therapy. Cancer Gene Ther. 2024;31(11):1632\u20131645.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"e_1_3_4_83_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-9433-3-1","article-title":"NF-kB inhibitor blocks B cell development at two checkpoints","volume":"3","author":"Feng B","year":"2004","unstructured":"Feng B, Cheng S, Pear WS, Liou H-C. NF-kB inhibitor blocks B cell development at two checkpoints. Med Immunol. 2004;3(1):1.","journal-title":"Med Immunol"},{"issue":"17","key":"e_1_3_4_84_1","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo Y","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019;62(17):7923\u20137940.","journal-title":"J Med Chem"},{"issue":"9","key":"e_1_3_4_85_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy DE","year":"2002","unstructured":"Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651\u2013662.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"e_1_3_4_86_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu X","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"e_1_3_4_87_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra S","year":"2025","unstructured":"Samra S, Bergerson JR, Freeman AF, Turvey SE. JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity. J Allergy Clin Immunol. 2025;155(2):357\u2013367.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"e_1_3_4_88_1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/jcmm.17228","article-title":"JAK-STAT core cancer pathway: an integrative cancer interactome analysis","volume":"26","author":"Erdogan F","year":"2022","unstructured":"Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, et al. JAK-STAT core cancer pathway: an integrative cancer interactome analysis. J Cell Mol Med. 2022;26(7):2049\u20132062.","journal-title":"J Cell Mol Med"},{"issue":"21","key":"e_1_3_4_89_1","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips RL","year":"2022","unstructured":"Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, Horvath CM, Darnell JE, Stark GR, O\u2019Shea JJ. The JAK-STAT pathway at 30: much learned, much more to do. Cell. 2022;185(21):3857\u20133876.","journal-title":"Cell"},{"issue":"6","key":"e_1_3_4_90_1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/cells9061451","article-title":"Targeting the JAK\/STAT signaling pathway using phytocompounds for cancer prevention and therapy","volume":"9","author":"Bose S","year":"2020","unstructured":"Bose S, Banerjee S, Mondal A, Chakraborty U, Pumarol J, Croley CR, Bishayee A. Targeting the JAK\/STAT signaling pathway using phytocompounds for cancer prevention and therapy. Cells. 2020;9(6):1451.","journal-title":"Cells"},{"issue":"3","key":"e_1_3_4_91_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2022.08.003","article-title":"STAT family of transcription factors in breast cancer: pathogenesis and therapeutic opportunities and challenges","volume":"86","author":"Wong GL","year":"2022","unstructured":"Wong GL, Manore SG, Doheny DL, Lo H-W. STAT family of transcription factors in breast cancer: pathogenesis and therapeutic opportunities and challenges. Semin Cancer Biol. 2022;86(Pt 3):84\u2013106.","journal-title":"Semin Cancer Biol"},{"key":"e_1_3_4_92_1","doi-asserted-by":"crossref","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu Q","year":"2023","unstructured":"Hu Q, Bian Q, Rong D, Wang L, Song J, Huang H-S, Zeng J, Mei J, Wang P-Y. JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol. 2023;11:1110765.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"e_1_3_4_93_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.smim.2013.12.005","article-title":"Toward a new STATe: the role of STATs in mitochondrial function","volume":"26","author":"Meier JA","year":"2014","unstructured":"Meier JA, Larner AC. Toward a new STATe: the role of STATs in mitochondrial function. Semin Immunol. 2014;26(1):20\u201328.","journal-title":"Semin Immunol"},{"issue":"5","key":"e_1_3_4_94_1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","article-title":"Malignant JAK-signaling: at the interface of inflammation and malignant transformation","volume":"39","author":"Perner F","year":"2025","unstructured":"Perner F, Pahl HL, Zeiser R, Heidel FH. Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia. 2025;39(5):1011\u20131030.","journal-title":"Leukemia"},{"issue":"2","key":"e_1_3_4_95_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.immuni.2012.01.010","article-title":"JAK\u2019s SOCS: a mechanism of inhibition","volume":"36","author":"Yoshimura A","year":"2012","unstructured":"Yoshimura A, Yasukawa H. JAK\u2019s SOCS: a mechanism of inhibition. Immunity. 2012;36(2):157\u2013159.","journal-title":"Immunity"},{"issue":"1","key":"e_1_3_4_96_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif F","year":"2017","unstructured":"Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15(1):23.","journal-title":"Cell Commun Signal"},{"key":"e_1_3_4_97_1","doi-asserted-by":"crossref","first-page":"1669688","DOI":"10.3389\/fimmu.2025.1669688","article-title":"JAK\/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders","volume":"16","author":"Djidjik R","year":"2025","unstructured":"Djidjik R, Lamara Mahammed L, Berkani LM, Allam I, Benmoussa AH, Gharnaout M, Belaid B. JAK\/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders. Front Immunol. 2025;16:1669688.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_4_98_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s43556-023-00151-1","article-title":"JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions","volume":"4","author":"Sarapultsev A","year":"2023","unstructured":"Sarapultsev A, Gusev E, Komelkova M, Utepova I, Luo S, Hu D. JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Mol Biomed. 2023;4(1):40.","journal-title":"Mol Biomed"},{"key":"e_1_3_4_99_1","doi-asserted-by":"crossref","first-page":"1023177","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang B","year":"2022","unstructured":"Huang B, Lang X, Li X. The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol. 2022;12:1023177.","journal-title":"Front Oncol"},{"issue":"11","key":"e_1_3_4_100_1","doi-asserted-by":"crossref","first-page":"e78728","DOI":"10.1371\/journal.pone.0078728","article-title":"NF-\u03baB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma","volume":"8","author":"McFarland BC","year":"2013","unstructured":"McFarland BC, Hong SW, Rajbhandari R, Twitty GB, Jr, Gray GK, Yu H, Benveniste EN, Nozell SE. NF-\u03baB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS One. 2013;8(11):e78728.","journal-title":"PLoS One"},{"issue":"4","key":"e_1_3_4_101_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41573-025-01336-9","article-title":"Pharmacological targeting of the JAK\u2013STAT pathway: new concepts and emerging indications","volume":"25","author":"Haikarainen T","year":"2026","unstructured":"Haikarainen T, Virtanen AT, Cravatt BF, Silvennoinen O. Pharmacological targeting of the JAK\u2013STAT pathway: new concepts and emerging indications. Nat Rev Drug Discov. 2026;25(4):268\u2013289.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"e_1_3_4_102_1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1089\/ars.2017.7387","article-title":"Targeting oncogenic nuclear factor kappa B signaling with redox-active agents for cancer treatment","volume":"30","author":"Fouani L","year":"2019","unstructured":"Fouani L, Kovacevic Z, Richardson DR. Targeting oncogenic nuclear factor kappa B signaling with redox-active agents for cancer treatment. Antioxid Redox Signal. 2019;30(8):1096\u20131123.","journal-title":"Antioxid Redox Signal"},{"issue":"8","key":"e_1_3_4_103_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/onc.2015.150","article-title":"Targeting JAK kinase in solid tumors: emerging opportunities and challenges","volume":"35","author":"Buchert M","year":"2016","unstructured":"Buchert M, Burns C, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016;35(8):939\u2013951.","journal-title":"Oncogene"},{"issue":"9","key":"e_1_3_4_104_1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/gb-2004-5-9-241","article-title":"The cyclooxygenases","volume":"5","author":"Chandrasekharan N","year":"2004","unstructured":"Chandrasekharan N, Simmons DL. The cyclooxygenases. Genome Biol. 2004;5(9):241.","journal-title":"Genome Biol"},{"issue":"47","key":"e_1_3_4_105_1","doi-asserted-by":"crossref","first-page":"44877","DOI":"10.1074\/jbc.M206788200","article-title":"Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides","volume":"277","author":"Kozak KR","year":"2002","unstructured":"Kozak KR, Crews BC, Morrow JD, Wang L-H, Ma YH, Weinander R, Jakobsson P-J, Marnett LJ. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277(47):44877\u201344885.","journal-title":"J Biol Chem"},{"issue":"4","key":"e_1_3_4_106_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bbalip.2014.12.015","article-title":"Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases","volume":"1851","author":"Urquhart P","year":"2015","unstructured":"Urquhart P, Nicolaou A, Woodward D. Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. Biochim Biophys Acta. 2015;1851(4):366\u2013376.","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"e_1_3_4_107_1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","article-title":"Cyclooxygenase in biology and disease","volume":"12","author":"Dubois RN","year":"1998","unstructured":"Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998;12(12):1063\u20131073.","journal-title":"FASEB J"},{"issue":"52","key":"e_1_3_4_108_1","doi-asserted-by":"crossref","first-page":"15451","DOI":"10.1021\/bi026938h","article-title":"The cyclooxygenase reaction mechanism","volume":"41","author":"Van der Donk WA","year":"2002","unstructured":"Van der Donk WA, Tsai A-L, Kulmacz RJ. The cyclooxygenase reaction mechanism. Biochemistry. 2002;41(52):15451\u201315458.","journal-title":"Biochemistry"},{"issue":"5","key":"e_1_3_4_109_1","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel N","year":"2019","unstructured":"Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. J Cell Physiol. 2019;234(5):5683\u20135699.","journal-title":"J Cell Physiol"},{"issue":"4","key":"e_1_3_4_110_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/carcin\/bgg006","article-title":"Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer","volume":"24","author":"Maih\u00f6fner C","year":"2003","unstructured":"Maih\u00f6fner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ, Colorectal Cancer Group. Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis. 2003;24(4):665\u2013671.","journal-title":"Carcinogenesis"},{"issue":"1","key":"e_1_3_4_111_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00384-006-0112-y","article-title":"NF-kappaB\/PPAR gamma and\/or AP-1\/PPAR gamma \u2018on\/off\u2019 switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression","volume":"22","author":"Konstantinopoulos PA","year":"2007","unstructured":"Konstantinopoulos PA, Vandoros GP, Sotiropoulou-Bonikou G, Kominea A, Papavassiliou AG. NF-kappaB\/PPAR gamma and\/or AP-1\/PPAR gamma \u2018on\/off\u2019 switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int J Colorectal Dis. 2007;22(1):57\u201368.","journal-title":"Int J Colorectal Dis"},{"key":"e_1_3_4_112_1","doi-asserted-by":"crossref","first-page":"1099811","DOI":"10.3389\/fonc.2023.1099811","article-title":"Cyclooxygenase-2-prostaglandin E2 pathway: a key player in tumor-associated immune cells","volume":"13","author":"Jin K","year":"2023","unstructured":"Jin K, Qian C, Lin J, Liu B. Cyclooxygenase-2-prostaglandin E2 pathway: a key player in tumor-associated immune cells. Front Oncol. 2023;13:1099811.","journal-title":"Front Oncol"},{"issue":"12","key":"e_1_3_4_113_1","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","article-title":"Activation of apoptosis signalling pathways by reactive oxygen species","volume":"1863","author":"Redza-Dutordoir M","year":"2016","unstructured":"Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta. 2016;1863(12):2977\u20132992.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"e_1_3_4_114_1","doi-asserted-by":"crossref","first-page":"e1633","DOI":"10.1002\/wsbm.1633","article-title":"Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment","volume":"16","author":"Bachari A","year":"2024","unstructured":"Bachari A, Nassar N, Schanknecht E, Telukutla S, Piva TJ, Mantri N. Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment. WIREs Mech Dis. 2024;16(1):e1633.","journal-title":"WIREs Mech Dis"},{"issue":"6","key":"e_1_3_4_115_1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00262-007-0417-x","article-title":"Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner","volume":"57","author":"Yaqub S","year":"2008","unstructured":"Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bj\u00f8rnbeth BA, Task\u00e9n K. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother. 2008;57(6):813\u2013821.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"e_1_3_4_116_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00915791","article-title":"Regulation of the immune response by prostaglandins","volume":"3","author":"Goodwin JS","year":"1983","unstructured":"Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983;3(4):295\u2013315.","journal-title":"J Clin Immunol"},{"issue":"7","key":"e_1_3_4_117_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.trecan.2024.05.006","article-title":"COX2-dependent suppression of anticancer immunity","volume":"10","author":"Lira MC","year":"2024","unstructured":"Lira MC, Galluzzi L, Vanpouille-Box C. COX2-dependent suppression of anticancer immunity. Trends Cancer. 2024;10(7):573\u2013575.","journal-title":"Trends Cancer"},{"issue":"1","key":"e_1_3_4_118_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu B","year":"2015","unstructured":"Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15(1):106.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"e_1_3_4_119_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaoncol.2025.6196","article-title":"Cancer incidence and mortality with aspirin in older adults: follow-up of the ASPREE trial","volume":"12","author":"Orchard SG","year":"2026","unstructured":"Orchard SG, Polekhina G, Zalcberg J, Bernstein W, Macrae F, Tie J, Gately L, Mar V, Millar J, Rodriguez LM, et al. Cancer incidence and mortality with aspirin in older adults: follow-up of the ASPREE trial. JAMA Oncol. 2026;12(3):285\u2013294.","journal-title":"JAMA Oncol"},{"issue":"6349","key":"e_1_3_4_120_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/354149a0","article-title":"A primary determinant for lipoxygenase positional specificity","volume":"354","author":"Sloane DL","year":"1991","unstructured":"Sloane DL, Leung R, Craik CS, Sigal E. A primary determinant for lipoxygenase positional specificity. Nature. 1991;354(6349):149\u2013152.","journal-title":"Nature"},{"key":"e_1_3_4_121_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.redox.2015.08.006","article-title":"The role of lipoxygenases in pathophysiology; new insights and future perspectives","volume":"6","author":"Mashima R","year":"2015","unstructured":"Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol. 2015;6:297\u2013310.","journal-title":"Redox Biol"},{"issue":"18","key":"e_1_3_4_122_1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41388-024-03016-1","article-title":"The role of human 5-Lipoxygenase (5-LO) in carcinogenesis \u2013 a question of canonical and non-canonical functions","volume":"43","author":"Kahnt AS","year":"2024","unstructured":"Kahnt AS, H\u00e4fner AK, Steinhilber D. The role of human 5-Lipoxygenase (5-LO) in carcinogenesis \u2013 a question of canonical and non-canonical functions. Oncogene. 2024;43(18):1319\u20131327.","journal-title":"Oncogene"},{"issue":"3","key":"e_1_3_4_123_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10555-007-9098-3","article-title":"Lipoxygenase metabolism: roles in tumor progression and survival","volume":"26","author":"Pidgeon GP","year":"2007","unstructured":"Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O\u2019Byrne K, Nie D, Honn KV. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 2007;26(3-4):503\u2013524.","journal-title":"Cancer Metastasis Rev"},{"key":"e_1_3_4_124_1","doi-asserted-by":"crossref","first-page":"115252","DOI":"10.1016\/j.bcp.2022.115252","article-title":"Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk","volume":"205","author":"Contursi A","year":"2022","unstructured":"Contursi A, Tacconelli S, Hofling U, Bruno A, Dovizio M, Ballerini P, Patrignani P. Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk. Biochem Pharmacol. 2022;205:115252.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"e_1_3_4_125_1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/ijc.22153","article-title":"What are cyclooxygenases and lipoxygenases doing in the driver\u2019s seat of carcinogenesis?","volume":"119","author":"F\u00fcrstenberger G","year":"2006","unstructured":"F\u00fcrstenberger G, Krieg P, M\u00fcller-Decker K, Habenicht AJ. What are cyclooxygenases and lipoxygenases doing in the driver\u2019s seat of carcinogenesis? Int J Cancer. 2006;119(10):2247\u20132254.","journal-title":"Int J Cancer"},{"issue":"31","key":"e_1_3_4_126_1","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2174\/1381612826666210101153216","article-title":"Lipoxygenase (LOX) pathway: a promising target to combat cancer","volume":"27","author":"Vishnupriya P","year":"2021","unstructured":"Vishnupriya P, Aparna A, Viswanadha VP. Lipoxygenase (LOX) pathway: a promising target to combat cancer. Curr Pharm Des. 2021;27(31):3349\u20133369.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"e_1_3_4_127_1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2174\/0929867326666191210104820","article-title":"Lipoxygenase inhibitors as cancer chemopreventives: discovery, recent developments and future perspectives","volume":"28","author":"Mahboubi-Rabbani M","year":"2021","unstructured":"Mahboubi-Rabbani M, Zarghi A. Lipoxygenase inhibitors as cancer chemopreventives: discovery, recent developments and future perspectives. Curr Med Chem. 2021;28(6):1143\u20131175.","journal-title":"Curr Med Chem"},{"issue":"3","key":"e_1_3_4_128_1","first-page":"190","article-title":"Redox regulation in anabolic and catabolic processes","volume":"9","author":"Dr\u00f6ge W.","year":"2006","unstructured":"Dr\u00f6ge W. Redox regulation in anabolic and catabolic processes. Curr Opin Clin Nutr Metab Care. 2006;9(3):190\u2013195.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"2","key":"e_1_3_4_129_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molcel.2012.09.025","article-title":"Physiological roles of mitochondrial reactive oxygen species","volume":"48","author":"Sena LA","year":"2012","unstructured":"Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48(2):158\u2013167.","journal-title":"Mol Cell"},{"key":"e_1_3_4_130_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4614-3573-0_6","article-title":"Molecular mechanisms of superoxide production by the mitochondrial respiratory chain","volume":"748","author":"Dr\u00f6se S","year":"2012","unstructured":"Dr\u00f6se S, Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv Exp Med Biol. 2012;748:145\u2013169.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"e_1_3_4_131_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.molmed.2017.03.004","article-title":"ROS in cancer: the burning question","volume":"23","author":"Chio IIC","year":"2017","unstructured":"Chio IIC, Tuveson DA. ROS in cancer: the burning question. Trends Mol Med. 2017;23(5):411\u2013429.","journal-title":"Trends Mol Med"},{"key":"e_1_3_4_132_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cotox.2017.11.002","article-title":"NF-\u03baB in oxidative stress","volume":"7","author":"Lingappan K.","year":"2018","unstructured":"Lingappan K. NF-\u03baB in oxidative stress. Curr Opin Toxicol. 2018;7:81\u201386.","journal-title":"Curr Opin Toxicol"},{"issue":"41","key":"e_1_3_4_133_1","first-page":"E2803","article-title":"Redox regulation of MAPK phosphatase 1 controls monocyte migration and macrophage recruitment","volume":"109","author":"Kim HS","year":"2012","unstructured":"Kim HS, Ullevig SL, Zamora D, Lee CF, Asmis R. Redox regulation of MAPK phosphatase 1 controls monocyte migration and macrophage recruitment. Proc Natl Acad Sci USA. 2012;109(41):E2803. E2812.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"e_1_3_4_134_1","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2014.164","article-title":"mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3","volume":"34","author":"Dodd KM","year":"2015","unstructured":"Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR. mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 2015;34(17):2239\u20132250.","journal-title":"Oncogene"},{"issue":"10","key":"e_1_3_4_135_1","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1111\/cas.15068","article-title":"Reactive oxygen species in cancer: current findings and future directions","volume":"112","author":"Nakamura H","year":"2021","unstructured":"Nakamura H, Takada K. Reactive oxygen species in cancer: current findings and future directions. Cancer Sci. 2021;112(10):3945\u20133952.","journal-title":"Cancer Sci"},{"issue":"1","key":"e_1_3_4_136_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1083\/jcb.201102095","article-title":"Signal transduction by reactive oxygen species","volume":"194","author":"Finkel T.","year":"2011","unstructured":"Finkel T. Signal transduction by reactive oxygen species. J Cell Biol. 2011;194(1):7\u201315.","journal-title":"J Cell Biol"},{"issue":"1","key":"e_1_3_4_137_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1196\/annals.1427.015","article-title":"The role of mitochondria in reactive oxygen species metabolism and signaling","volume":"1147","author":"Starkov AA.","year":"2008","unstructured":"Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann N Y Acad Sci. 2008;1147(1):37\u201352.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"e_1_3_4_138_1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini C","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931\u2013947.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"e_1_3_4_139_1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/antiox14081002","article-title":"Living on the edge: ROS homeostasis in cancer cells and its potential as a therapeutic target","volume":"14","author":"Brandl N","year":"2025","unstructured":"Brandl N, Seitz R, Sendtner N, M\u00fcller M, G\u00fclow K. Living on the edge: ROS homeostasis in cancer cells and its potential as a therapeutic target. Antioxidants. 2025;14(8):1002.","journal-title":"Antioxidants"},{"issue":"1","key":"e_1_3_4_140_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05608.x","article-title":"Role of oxidative\/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation","volume":"1203","author":"Azad N","year":"2010","unstructured":"Azad N, Iyer A, Vallyathan V, Wang L, Castranova V, Stehlik C, Rojanasakul Y. Role of oxidative\/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation. Ann N Y Acad Sci. 2010;1203(1):1\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"e_1_3_4_141_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2008.02.044","article-title":"Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy","volume":"266","author":"Ushio-Fukai M","year":"2008","unstructured":"Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008;266(1):37\u201352.","journal-title":"Cancer Lett"},{"issue":"8","key":"e_1_3_4_142_1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux C","year":"2024","unstructured":"Glorieux C, Liu S, Trachootham D, Huang P. Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discov. 2024;23(8):583\u2013606.","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"e_1_3_4_143_1","doi-asserted-by":"crossref","first-page":"2004433","DOI":"10.1002\/advs.202004433","article-title":"Cytokines: from clinical significance to quantification","volume":"8","author":"Liu C","year":"2021","unstructured":"Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: from clinical significance to quantification. Adv Sci. 2021;8(15):2004433.","journal-title":"Adv Sci"},{"issue":"4","key":"e_1_3_4_144_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper DJ","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237\u2013253.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"e_1_3_4_145_1","doi-asserted-by":"crossref","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann TA.","year":"2018","unstructured":"Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(12):a028472.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"8","key":"e_1_3_4_146_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska D","year":"2021","unstructured":"Briukhovetska D, D\u00f6rr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21(8):481\u2013499.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"e_1_3_4_147_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/JLB.5MIR0420-055R","article-title":"Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy","volume":"108","author":"Bendickova K","year":"2020","unstructured":"Bendickova K, Fric J. Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy. J Leukoc Biol. 2020;108(1):427\u2013437.","journal-title":"J Leukoc Biol"},{"issue":"4","key":"e_1_3_4_148_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/JLB.2RI0717-278R","article-title":"Biology of IL-2 and its therapeutic modulation: mechanisms and strategies","volume":"103","author":"Mitra S","year":"2018","unstructured":"Mitra S, Leonard WJ. Biology of IL-2 and its therapeutic modulation: mechanisms and strategies. J Leukoc Biol. 2018;103(4):643\u2013655.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"e_1_3_4_149_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad S","year":"2023","unstructured":"Muhammad S, Fan T, Hai Y, Gao Y, He J. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer. 2023;22(1):121.","journal-title":"Mol Cancer"},{"issue":"1","key":"e_1_3_4_150_1","doi-asserted-by":"crossref","first-page":"e20190418","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva M","year":"2019","unstructured":"Saraiva M, Vieira P, O\u2019garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2019;217(1):e20190418.","journal-title":"J Exp Med"},{"issue":"4","key":"e_1_3_4_151_1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","article-title":"IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation","volume":"50","author":"Ouyang W","year":"2019","unstructured":"Ouyang W, O\u2019Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019;50(4):871\u2013891.","journal-title":"Immunity"},{"issue":"4","key":"e_1_3_4_152_1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.drudis.2021.01.002","article-title":"Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights","volume":"26","author":"Kumar S","year":"2021","unstructured":"Kumar S, Singh SK, Rana B, Rana A. Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today. 2021;26(4):951\u2013967.","journal-title":"Drug Discov Today"},{"key":"e_1_3_4_153_1","doi-asserted-by":"crossref","first-page":"575597","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized interleukin-12 for cancer immunotherapy","volume":"11","author":"Nguyen KG","year":"2020","unstructured":"Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, Zaharoff DA. Localized interleukin-12 for cancer immunotherapy. Front Immunol. 2020;11:575597.","journal-title":"Front Immunol"},{"issue":"7","key":"e_1_3_4_154_1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.20041389","article-title":"Coordinate expression and trans presentation of interleukin (IL)-15R\u03b1 and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis","volume":"200","author":"Burkett PR","year":"2004","unstructured":"Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15R\u03b1 and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med. 2004;200(7):825\u2013834.","journal-title":"J Exp Med"},{"issue":"3","key":"e_1_3_4_155_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano T.","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127\u2013148.","journal-title":"Int Immunol"},{"issue":"14","key":"e_1_3_4_156_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3889\/oamjms.2019.589","article-title":"IL-6 activities in the tumour microenvironment. Part 1","volume":"7","author":"Chonov DC","year":"2019","unstructured":"Chonov DC, Ignatova MMK, Ananiev JR, Gulubova MV. IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Med Sci. 2019;7(14):2391\u20132398.","journal-title":"Open Access Maced J Med Sci"},{"issue":"10","key":"e_1_3_4_157_1","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3390\/cancers17101691","article-title":"Interleukin-6 is a crucial factor in shaping the inflammatory tumor microenvironment in ovarian cancer and determining its hot or cold nature with diagnostic and prognostic utilities","volume":"17","author":"Amer H","year":"2025","unstructured":"Amer H, Flanagan KL, Kampan NC, Itsiopoulos C, Scott CL, Kartikasari AE, Plebanski M. Interleukin-6 is a crucial factor in shaping the inflammatory tumor microenvironment in ovarian cancer and determining its hot or cold nature with diagnostic and prognostic utilities. Cancers (Basel). 2025;17(10):1691.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"e_1_3_4_158_1","doi-asserted-by":"crossref","first-page":"e007530","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler MF","year":"2023","unstructured":"Soler MF, Abaurrea A, Azcoaga P, Araujo AM, Caffarel MM. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer. 2023;11(11):e007530.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_159_1","first-page":"141","article-title":"TNF in the inflammatory response","volume":"74","author":"Mannel DN","year":"1999","unstructured":"Mannel DN, Echtenacher B. TNF in the inflammatory response. Chem Immunol. 1999;74:141\u2013141.","journal-title":"Chem Immunol"},{"issue":"1","key":"e_1_3_4_160_1","doi-asserted-by":"crossref","first-page":"184394","DOI":"10.1016\/j.bbamem.2024.184394","article-title":"TNF receptors: structure-function relationships and therapeutic targeting strategies","volume":"1867","author":"Lo CH.","year":"2025","unstructured":"Lo CH. TNF receptors: structure-function relationships and therapeutic targeting strategies. Biochim Biophys Acta Biomembr. 2025;1867(1):184394.","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"4","key":"e_1_3_4_161_1","doi-asserted-by":"crossref","first-page":"e70313","DOI":"10.1002\/ctm2.70313","article-title":"Angiogenesis and targeted therapy in the tumour microenvironment: from basic to clinical practice","volume":"15","author":"Yang S","year":"2025","unstructured":"Yang S, Fang Y, Ma Y, Wang F, Wang Y, Jia J, Yang Y, Sun W, Zhou Q, Li Z. Angiogenesis and targeted therapy in the tumour microenvironment: from basic to clinical practice. Clin Transl Med. 2025;15(4):e70313.","journal-title":"Clin Transl Med"},{"issue":"1","key":"e_1_3_4_162_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41698-025-00990-x","article-title":"The role of tumor necrosis factor receptor superfamily in cancer: insights into oncogenesis, progression, and therapeutic strategies","volume":"9","author":"Xu J.","year":"2025","unstructured":"Xu J. The role of tumor necrosis factor receptor superfamily in cancer: insights into oncogenesis, progression, and therapeutic strategies. NPJ Precis Oncol. 2025;9(1):275.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"e_1_3_4_163_1","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1038\/s41598-025-87092-7","article-title":"Role of CXCL10 released from osteocytes in response to TNF-\u03b1 stimulation on osteoclasts","volume":"15","author":"Miura M","year":"2025","unstructured":"Miura M, Kitaura H, Ohori F, Narita K, Ren J, Noguchi T, Marahleh A, Ma J, Lin A, Fan Z, et al. Role of CXCL10 released from osteocytes in response to TNF-\u03b1 stimulation on osteoclasts. Sci Rep. 2025;15(1):3040.","journal-title":"Sci Rep"},{"issue":"6","key":"e_1_3_4_164_1","doi-asserted-by":"crossref","first-page":"e70231","DOI":"10.1002\/mco2.70231","article-title":"Myeloid-derived suppressor cells in cancer: mechanistic insights and targeted therapeutic innovations","volume":"6","author":"Hu T","year":"2025","unstructured":"Hu T, Zhai J, Yang Z, Peng J, Wang C, Liu X, Li Y, Yao J, Chen F, Li H, et al. Myeloid-derived suppressor cells in cancer: mechanistic insights and targeted therapeutic innovations. MedComm. 2025;6(6):e70231.","journal-title":"MedComm"},{"key":"e_1_3_4_165_1","doi-asserted-by":"crossref","first-page":"918254","DOI":"10.3389\/fimmu.2022.918254","article-title":"Elevation of circulating TNF receptor 2 in cancer: a systematic meta-analysis for its potential as a diagnostic cancer biomarker","volume":"13","author":"Kartikasari AE","year":"2022","unstructured":"Kartikasari AE, Cassar E, Razqan MA, Szydzik C, Huertas CS, Mitchell A, Plebanski M. Elevation of circulating TNF receptor 2 in cancer: a systematic meta-analysis for its potential as a diagnostic cancer biomarker. Front Immunol. 2022;13:918254.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_4_166_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s43556-025-00381-5","article-title":"Interferon signaling pathways in health and disease","volume":"6","author":"Wen C","year":"2025","unstructured":"Wen C, Lan Q, Wang Y, Ni Y, Wong AST, Liu D. Interferon signaling pathways in health and disease. Mol Biomed. 2025;6(1):135.","journal-title":"Mol Biomed"},{"issue":"17","key":"e_1_3_4_167_1","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1016\/j.cell.2025.06.044","article-title":"Interferons in health and disease","volume":"188","author":"Boehmer D","year":"2025","unstructured":"Boehmer D, Zanoni I. Interferons in health and disease. Cell. 2025;188(17):4480\u20134504.","journal-title":"Cell"},{"issue":"4","key":"e_1_3_4_168_1","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1152\/physrev.00047.2024","article-title":"Type I interferons in health and disease: molecular aspects and clinical implications","volume":"105","author":"Mavragani CP","year":"2025","unstructured":"Mavragani CP, Crow MK. Type I interferons in health and disease: molecular aspects and clinical implications. Physiol Rev. 2025;105(4):2537\u20132587.","journal-title":"Physiol Rev"},{"issue":"10","key":"e_1_3_4_169_1","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1002\/mco2.714","article-title":"The interaction of innate immune and adaptive immune system","volume":"5","author":"Wang R","year":"2024","unstructured":"Wang R, Lan C, Benlagha K, Camara NOS, Miller H, Kubo M, Heegaard S, Lee P, Yang L, Forsman H, et al. The interaction of innate immune and adaptive immune system. MedComm. 2024;5(10):e714.","journal-title":"MedComm"},{"issue":"5","key":"e_1_3_4_170_1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/cancers13051037","article-title":"Type I and II interferons in the anti-tumor immune response","volume":"13","author":"Fenton SE","year":"2021","unstructured":"Fenton SE, Saleiro D, Platanias LC. Type I and II interferons in the anti-tumor immune response. Cancers (Basel). 2021;13(5):1037.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"e_1_3_4_171_1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci JL","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540\u20131554.e12. e1512.","journal-title":"Cell"},{"issue":"5","key":"e_1_3_4_172_1","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-\u03b1 directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity","volume":"186","author":"Terawaki S","year":"2011","unstructured":"Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, Honjo T. IFN-\u03b1 directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. 2011;186(5):2772\u20132779.","journal-title":"J Immunol"},{"issue":"1","key":"e_1_3_4_173_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic D","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res. 2020;8(1):49. 2020.","journal-title":"Biomark Res"},{"key":"e_1_3_4_174_1","doi-asserted-by":"crossref","first-page":"101280","DOI":"10.1016\/j.smim.2019.05.002","article-title":"IFN-\u03b3: a cytokine at the right time, is in the right place","volume":"43","author":"Burke JD","year":"2019","unstructured":"Burke JD, Young HA. IFN-\u03b3: a cytokine at the right time, is in the right place. Semin Immunol. 2019;43:101280.","journal-title":"Semin Immunol"},{"issue":"6587","key":"e_1_3_4_175_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/382171a0","article-title":"Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells","volume":"382","author":"Thierfelder WE","year":"1996","unstructured":"Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996;382(6587):171\u2013174.","journal-title":"Nature"},{"issue":"4","key":"e_1_3_4_176_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-\u03b3: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu X","year":"2009","unstructured":"Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-\u03b3: implications for immune responses and autoimmune diseases. Immunity. 2009;31(4):539\u2013550.","journal-title":"Immunity"},{"issue":"1","key":"e_1_3_4_177_1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith JW","year":"2014","unstructured":"Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32(1):659\u2013702.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"e_1_3_4_178_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth N","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u2013572.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"e_1_3_4_179_1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill F.","year":"2004","unstructured":"Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540\u2013550.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"e_1_3_4_180_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2006.12.012","article-title":"CCL2\/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers","volume":"252","author":"Huang B","year":"2007","unstructured":"Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, Liu Y, Li D, Yuan Y, Zhang G-M, et al. CCL2\/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007;252(1):86\u201392.","journal-title":"Cancer Lett"},{"issue":"2","key":"e_1_3_4_181_1","doi-asserted-by":"crossref","first-page":"e000764","DOI":"10.1136\/jitc-2020-000764","article-title":"Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4","volume":"8","author":"Marshall LA","year":"2020","unstructured":"Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, Hu DX, Jackson JJ, Pookot D, Sanchez J, et al. Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4. J Immunother Cancer. 2020;8(2):e000764.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"e_1_3_4_182_1","first-page":"292376","article-title":"The inflammatory chemokine CCL5 and cancer progression","volume":"2014","author":"Aldinucci D","year":"2014","unstructured":"Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014;2014(1):292376.","journal-title":"Mediators Inflamm"},{"key":"e_1_3_4_183_1","doi-asserted-by":"crossref","first-page":"156344","DOI":"10.1016\/j.cyto.2023.156344","article-title":"Tamoxifen as a modulator of CXCL12-CXCR4-CXCR7 chemokine axis: a breast cancer and glioblastoma view","volume":"170","author":"Gon\u00e7alves TL","year":"2023","unstructured":"Gon\u00e7alves TL, de Ara\u00fajo LP, Ferrer VP. Tamoxifen as a modulator of CXCL12-CXCR4-CXCR7 chemokine axis: a breast cancer and glioblastoma view. Cytokine. 2023;170:156344.","journal-title":"Cytokine"},{"issue":"1","key":"e_1_3_4_184_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi M","year":"2024","unstructured":"Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, Dai Z. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9(1):176.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"e_1_3_4_185_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2007.05.013","article-title":"Role of chemokines in tumor growth","volume":"256","author":"Raman D","year":"2007","unstructured":"Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007;256(2):137\u2013165.","journal-title":"Cancer Lett"},{"issue":"1","key":"e_1_3_4_186_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.coi.2009.12.004","article-title":"The inflammasomes: mechanisms of activation and function","volume":"22","author":"Latz E.","year":"2010","unstructured":"Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol. 2010;22(1):28\u201333.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"e_1_3_4_187_1","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1002\/mco2.391","article-title":"Inflammasome: structure, biological functions, and therapeutic targets","volume":"4","author":"Dai Y","year":"2023","unstructured":"Dai Y, Zhou J, Shi C. Inflammasome: structure, biological functions, and therapeutic targets. MedComm (2020). 2023;4(5):e391.","journal-title":"MedComm (2020)"},{"issue":"7371","key":"e_1_3_4_188_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki N","year":"2011","unstructured":"Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, et al. Non-canonical inflammasome activation targets caspase-11. Nature. 2011;479(7371):117\u2013121.","journal-title":"Nature"},{"issue":"7","key":"e_1_3_4_189_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz P","year":"2016","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407\u2013420.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"e_1_3_4_190_1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00018-015-2123-8","article-title":"NLR-regulated pathways in cancer: opportunities and obstacles for therapeutic interventions","volume":"73","author":"Sharma N","year":"2016","unstructured":"Sharma N, Jha S. NLR-regulated pathways in cancer: opportunities and obstacles for therapeutic interventions. Cell Mol Life Sci. 2016;73(9):1741\u20131764.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"e_1_3_4_191_1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 inflammasome in cancer and metabolic diseases","volume":"22","author":"Sharma BR","year":"2021","unstructured":"Sharma BR, Kanneganti T-D. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. 2021;22(5):550\u2013559.","journal-title":"Nat Immunol"},{"issue":"9","key":"e_1_3_4_192_1","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.7150\/thno.71086","article-title":"Pyroptosis in inflammatory diseases and cancer","volume":"12","author":"Rao Z","year":"2022","unstructured":"Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao C, Liu W, Deng H, Li J, Ning P, et al. Pyroptosis in inflammatory diseases and cancer. Theranostics. 2022;12(9):4310\u20134329.","journal-title":"Theranostics"},{"issue":"1","key":"e_1_3_4_193_1","doi-asserted-by":"crossref","first-page":"36107","DOI":"10.1038\/srep36107","article-title":"Targeting inflammasome\/IL-1 pathways for cancer immunotherapy","volume":"6","author":"Guo B","year":"2016","unstructured":"Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome\/IL-1 pathways for cancer immunotherapy. Sci Rep. 2016;6(1):36107.","journal-title":"Sci Rep"},{"issue":"24","key":"e_1_3_4_194_1","doi-asserted-by":"crossref","first-page":"13689","DOI":"10.3390\/ijms252413689","article-title":"Therapeutic significance of NLRP3 inflammasome in cancer: friend or foe?","volume":"25","author":"Jalali AM","year":"2024","unstructured":"Jalali AM, Mitchell KJ, Pompoco C, Poludasu S, Tran S, Ramana KV. Therapeutic significance of NLRP3 inflammasome in cancer: friend or foe? Int J Mol Sci. 2024;25(24):13689.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"e_1_3_4_195_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7150\/jca.101285","article-title":"NLRP3 promotes the proliferation and metastasis of colorectal cancer by regulating the S6K1-GLI1 signaling pathway","volume":"16","author":"Li S","year":"2025","unstructured":"Li S, Wang X, Hong L, Zhuang Z, Yang P, Chen Y, Yao Y, Jiang L, Zhu X, Wang B. NLRP3 promotes the proliferation and metastasis of colorectal cancer by regulating the S6K1-GLI1 signaling pathway. J Cancer. 2025;16(2):521\u2013532.","journal-title":"J Cancer"},{"key":"e_1_3_4_196_1","doi-asserted-by":"crossref","first-page":"1713259","DOI":"10.3389\/fphar.2025.1713259","article-title":"Molecular insights into NLRP3 inflammasome and miRNA modulation in oral cancer","volume":"16","author":"Mannino D","year":"2025","unstructured":"Mannino D, D\u2019Ariano M, Bello I, Paterniti I, Casili G, Panza E. Molecular insights into NLRP3 inflammasome and miRNA modulation in oral cancer. Front Pharmacol. 2025;16:1713259.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_197_1","doi-asserted-by":"crossref","first-page":"1649517","DOI":"10.3389\/fimmu.2025.1649517","article-title":"Dual signaling cascade regulating gut-lung axis in Interleukin-6\/Interleukin-17 for NSCLC immuno pathogenesis","volume":"16","author":"Khilwani R","year":"2025","unstructured":"Khilwani R, Singh S. Dual signaling cascade regulating gut-lung axis in Interleukin-6\/Interleukin-17 for NSCLC immuno pathogenesis. Front Immunol. 2025;16:1649517.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_4_198_1","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s12967-025-06665-2","article-title":"Targeting inflammasomes as an immunotherapeutic strategy for cancer","volume":"23","author":"Huang L","year":"2025","unstructured":"Huang L, Chen X, Liu R, Nan D, Bao W, Yang L, Dai X, Tang J, Zhang H, Lu Y. Targeting inflammasomes as an immunotherapeutic strategy for cancer. J Transl Med. 2025;23(1):634.","journal-title":"J Transl Med"},{"issue":"4","key":"e_1_3_4_199_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/ijmm.2023.5238","article-title":"Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases","volume":"51","author":"Zhang X","year":"2023","unstructured":"Zhang X, Wang Z, Zheng Y, Yu Q, Zeng M, Bai L, Yang L, Guo M, Jiang X, Gan J. Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases. Int J Mol Med. 2023;51(4):35.","journal-title":"Int J Mol Med"},{"key":"e_1_3_4_200_1","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fimmu.2020.01444","article-title":"NLRP3 inflammasome activation in cancer: a double-edged sword","volume":"11","author":"Hamarsheh S. a","year":"2020","unstructured":"Hamarsheh S. a, Zeiser R. NLRP3 inflammasome activation in cancer: a double-edged sword. Front Immunol. 2020;11:1444.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_4_201_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo NA","year":"2019","unstructured":"Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, et al. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120(1):45\u201353.","journal-title":"Br J Cancer"},{"key":"e_1_3_4_202_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coi.2014.01.001","article-title":"The immune contexture of primary and metastatic human tumours","volume":"27","author":"Giraldo NA","year":"2014","unstructured":"Giraldo NA, Becht E, Remark R, Damotte D, Saut\u00e8s-Fridman C, Fridman WH. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol. 2014;27:8\u201315.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"e_1_3_4_203_1","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s00432-022-04399-y","article-title":"Cancer-associated inflammation: pathophysiology and clinical significance","volume":"149","author":"P\u0119czek P","year":"2023","unstructured":"P\u0119czek P, Gajda M, Rutkowski K, Fudalej M, Depta\u0142a A, Badowska-Kozakiewicz AM. Cancer-associated inflammation: pathophysiology and clinical significance. J Cancer Res Clin Oncol. 2023;149(6):2657\u20132672.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"e_1_3_4_204_1","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1172\/JCI80007","article-title":"Immunity, inflammation, and cancer: an eternal fight between good and evil","volume":"125","author":"Shalapour S","year":"2015","unstructured":"Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125(9):3347\u20133355.","journal-title":"J Clin Invest"},{"issue":"2","key":"e_1_3_4_205_1","doi-asserted-by":"crossref","first-page":"e70599","DOI":"10.1002\/mco2.70599","article-title":"Tumor-associated macrophages as therapeutic targets: deciphering interaction networks and advancing clinical translation","volume":"7","author":"Bao W","year":"2026","unstructured":"Bao W, Qu X, Wang Y, Huang D, Zhang H, Dong M, Sun H, Yang Z, Li X. Tumor-associated macrophages as therapeutic targets: deciphering interaction networks and advancing clinical translation. MedComm (2020). 2026;7(2):e70599.","journal-title":"MedComm (2020)"},{"issue":"9","key":"e_1_3_4_206_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41423-023-01061-6","article-title":"Roles of macrophages in tumor development: a spatiotemporal perspective","volume":"20","author":"Bied M","year":"2023","unstructured":"Bied M, Ho WW, Ginhoux F, Bl\u00e9riot C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol. 2023;20(9):983\u2013992.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"e_1_3_4_207_1","doi-asserted-by":"crossref","first-page":"e70547","DOI":"10.1002\/mco2.70547","article-title":"The role of macrophages in cancer: from basic research to clinical applications","volume":"7","author":"Liu Z","year":"2026","unstructured":"Liu Z, Li Y, Cao J, Qiu Y, Yu K, Deng S. The role of macrophages in cancer: from basic research to clinical applications. MedComm (2020). 2026;7(1):e70547.","journal-title":"MedComm (2020)"},{"issue":"8","key":"e_1_3_4_208_1","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S1470-2045(17)30536-3","article-title":"Preventive therapy for cancer","volume":"18","author":"Cuzick J.","year":"2017","unstructured":"Cuzick J. Preventive therapy for cancer. Lancet Oncol. 2017;18(8):e472\u2013e482.","journal-title":"Lancet Oncol"},{"issue":"7","key":"e_1_3_4_209_1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cgh.2021.02.014","article-title":"AGA clinical practice update on chemoprevention for colorectal neoplasia: expert review","volume":"19","author":"Liang PS","year":"2021","unstructured":"Liang PS, Shaukat A, Crockett SD. AGA clinical practice update on chemoprevention for colorectal neoplasia: expert review. Clin Gastroenterol Hepatol. 2021;19(7):1327\u20131336.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_4_210_1","doi-asserted-by":"crossref","first-page":"713859","DOI":"10.1155\/2013\/713859","article-title":"Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma","volume":"2013","author":"Tang Q","year":"2013","unstructured":"Tang Q, Li J, Zhu H, Li P, Zou Z, Xiao Y. Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm. 2013;2013:713859\u2013713813.","journal-title":"Mediators Inflamm"},{"key":"e_1_3_4_211_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.molimm.2019.11.014","article-title":"Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor","volume":"117","author":"Li BH","year":"2020","unstructured":"Li BH, Garstka MA, Li ZF. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol Immunol. 2020;117:201\u2013215.","journal-title":"Mol Immunol"},{"issue":"1","key":"e_1_3_4_212_1","doi-asserted-by":"crossref","first-page":"1580967","DOI":"10.1155\/2016\/1580967","article-title":"Reactive oxygen species regulate T cell immune response in the tumor microenvironment","volume":"2016","author":"Chen X","year":"2016","unstructured":"Chen X, Song M, Zhang B, Zhang Y. Reactive oxygen species regulate T cell immune response in the tumor microenvironment. Oxid Med Cell Longev. 2016;2016(1):1580967.","journal-title":"Oxid Med Cell Longev"},{"key":"e_1_3_4_213_1","doi-asserted-by":"crossref","first-page":"1688699","DOI":"10.3389\/fimmu.2025.1688699","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang X","year":"2025","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;16:1688699.","journal-title":"Front Immunol"},{"issue":"2","key":"e_1_3_4_214_1","doi-asserted-by":"crossref","first-page":"189536","DOI":"10.1016\/j.bbcan.2026.189536","article-title":"Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade","volume":"1881","author":"Wang X","year":"2026","unstructured":"Wang X, Wang J, Wang Q, Ding G, Huang Y, Feng Y. Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade. Biochim Biophys Acta Rev Cancer. 2026;1881(2):189536.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"e_1_3_4_215_1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.neo.2018.05.002","article-title":"Carcinogenesis as a result of multiple inflammatory and oxidative hits: a comprehensive review from tumor microenvironment to gut microbiota","volume":"20","author":"Morgillo F","year":"2018","unstructured":"Morgillo F, Dallio M, Della Corte CM, Gravina AG, Viscardi G, Loguercio C, Ciardiello F, Federico A. Carcinogenesis as a result of multiple inflammatory and oxidative hits: a comprehensive review from tumor microenvironment to gut microbiota. Neoplasia. 2018;20(7):721\u2013733.","journal-title":"Neoplasia"},{"issue":"2","key":"e_1_3_4_216_1","doi-asserted-by":"crossref","first-page":"e70605","DOI":"10.1002\/mco2.70605","article-title":"Inflammation and cancer: molecular mechanisms and therapeutic targets","volume":"7","author":"Liu X","year":"2026","unstructured":"Liu X, Wang Z, Zhu H, Han Y, Ji Q. Inflammation and cancer: molecular mechanisms and therapeutic targets. MedComm (2020). 2026;7(2):e70605.","journal-title":"MedComm (2020)"},{"issue":"6","key":"e_1_3_4_217_1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00404-020-05559-6","article-title":"COX-2-PGE(2)-EPs in gynecological cancers","volume":"301","author":"Ye Y","year":"2020","unstructured":"Ye Y, Wang X, Jeschke U, von Sch\u00f6nfeldt V. COX-2-PGE(2)-EPs in gynecological cancers. Arch Gynecol Obstet. 2020;301(6):1365\u20131375. .","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"e_1_3_4_218_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu B","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_4_219_1","doi-asserted-by":"crossref","first-page":"1385479","DOI":"10.3389\/fphar.2024.1385479","article-title":"Inflammation and cancer: friend or foe?","volume":"15","author":"Turizo-Smith AD","year":"2024","unstructured":"Turizo-Smith AD, C\u00f3rdoba-Hernandez S, Mej\u00eda-Guarnizo LV, Monroy-Camacho PS, Rodr\u00edguez-Garc\u00eda JA. Inflammation and cancer: friend or foe? Front Pharmacol. 2024;15:1385479.","journal-title":"Front Pharmacol"},{"issue":"10","key":"e_1_3_4_220_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang JD","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"e_1_3_4_221_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","article-title":"Long-term effects of hepatitis b immunization of infants in preventing liver cancer","volume":"151","author":"Chang MH","year":"2016","unstructured":"Chang MH, You SL, Chen CJ, Liu CJ, Lai MW, Wu TC, Wu SF, Lee CM, Yang SS, Chu HC, et al. Long-term effects of hepatitis b immunization of infants in preventing liver cancer. Gastroenterology. 2016;151(3):472\u2013480.","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_3_4_222_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/SLA.0000000000000858","article-title":"Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial","volume":"261","author":"Huang G","year":"2015","unstructured":"Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261(1):56\u201366.","journal-title":"Ann Surg"},{"issue":"6","key":"e_1_3_4_223_1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2020.01.007","article-title":"Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B","volume":"72","author":"Papatheodoridis GV","year":"2020","unstructured":"Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol. 2020;72(6):1088\u20131096.","journal-title":"J Hepatol"},{"issue":"14","key":"e_1_3_4_224_1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei J","year":"2020","unstructured":"Lei J, Ploner A, Elfstr\u00f6m KM, Wang J, Roth A, Fang F, Sundstr\u00f6m K, Dillner J, Spar\u00e9n P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340\u20131348.","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_3_4_225_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"M\u00fcnz C.","year":"2019","unstructured":"M\u00fcnz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol. 2019;17(11):691\u2013700.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"e_1_3_4_226_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMoa1708423","article-title":"Helicobacter pylori therapy for the prevention of metachronous gastric cancer","volume":"378","author":"Choi IJ","year":"2018","unstructured":"Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378(12):1085\u20131095.","journal-title":"N Engl J Med"},{"issue":"6369","key":"e_1_3_4_227_1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1126\/science.aal5240","article-title":"Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer","volume":"358","author":"Bullman S","year":"2017","unstructured":"Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358(6369):1443\u20131448.","journal-title":"Science"},{"issue":"4","key":"e_1_3_4_228_1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chom.2017.03.006","article-title":"Autoreactive T cells and chronic fungal infection drive esophageal carcinogenesis","volume":"21","author":"Zhu F","year":"2017","unstructured":"Zhu F, Willette-Brown J, Song NY, Lomada D, Song Y, Xue L, Gray Z, Zhao Z, Davis SR, Sun Z, et al. Autoreactive T cells and chronic fungal infection drive esophageal carcinogenesis. Cell Host Microbe. 2017;21(4):478\u2013493.","journal-title":"Cell Host Microbe"},{"issue":"12","key":"e_1_3_4_229_1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","author":"Bibbins-Domingo K","year":"2016","unstructured":"Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(12):836\u2013845.","journal-title":"Ann Intern Med"},{"issue":"6","key":"e_1_3_4_230_1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamaoncol.2015.6396","article-title":"Population-wide impact of long-term use of aspirin and the risk for cancer","volume":"2","author":"Cao Y","year":"2016","unstructured":"Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, Spiegelman D, Fuchs CS, Giovannucci EL, Chan AT. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2(6):762\u2013769.","journal-title":"JAMA Oncol"},{"issue":"3","key":"e_1_3_4_231_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djaa114","article-title":"Effect of aspirin on cancer incidence and mortality in older adults","volume":"113","author":"McNeil JJ","year":"2021","unstructured":"McNeil JJ, Gibbs P, Orchard SG, Lockery JE, Bernstein WB, Cao Y, Ford L, Haydon A, Kirpach B, Macrae F, et al. Effect of aspirin on cancer incidence and mortality in older adults. J Natl Cancer Inst. 2021;113(3):258\u2013265.","journal-title":"J Natl Cancer Inst"},{"issue":"10240","key":"e_1_3_4_232_1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn J","year":"2020","unstructured":"Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, M\u00f6slein G, McRonald FE, Bertario L, Evans DG, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855\u20131863.","journal-title":"Lancet"},{"issue":"12","key":"e_1_3_4_233_1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/jama.298.12.1412","article-title":"Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease","volume":"298","author":"Chan AO","year":"2007","unstructured":"Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM, Chan CK, et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA. 2007;298(12):1412\u20131419.","journal-title":"JAMA"},{"issue":"21","key":"e_1_3_4_234_1","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter JN","year":"2005","unstructured":"Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184\u20132192.","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_3_4_235_1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1136\/gutjnl-2018-317714","article-title":"Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients","volume":"68","author":"Cheung KS","year":"2019","unstructured":"Cheung KS, Chen L, Chan EW, Seto WK, Wong ICK, Leung WK. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gut. 2019;68(11):1979\u20131985.","journal-title":"Gut"},{"issue":"1","key":"e_1_3_4_236_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale KM","year":"2006","unstructured":"Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74\u201380.","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_4_237_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jamaoncol.2017.2752","article-title":"Examining bias in studies of statin treatment and survival in patients with cancer","volume":"4","author":"Emilsson L","year":"2018","unstructured":"Emilsson L, Garc\u00eda-Alb\u00e9niz X, Logan RW, Caniglia EC, Kalager M, Hern\u00e1n MA. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. 2018;4(1):63\u201370.","journal-title":"JAMA Oncol"},{"issue":"5","key":"e_1_3_4_238_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41571-020-00459-9","article-title":"Targeting cancer-promoting inflammation \u2013 have anti-inflammatory therapies come of age?","volume":"18","author":"Hou J","year":"2021","unstructured":"Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation \u2013 have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18(5):261\u2013279.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"e_1_3_4_239_1","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/annonc\/mdt150","article-title":"Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis","volume":"24","author":"Singh PP","year":"2013","unstructured":"Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol. 2013;24(7):1721\u20131730.","journal-title":"Ann Oncol"},{"issue":"35","key":"e_1_3_4_240_1","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2016.67.4044","article-title":"Type 2 diabetes mellitus and cancer: the role of pharmacotherapy","volume":"34","author":"Shlomai G","year":"2016","unstructured":"Shlomai G, Neel B, LeRoith D, Gallagher EJ. Type 2 diabetes mellitus and cancer: the role of pharmacotherapy. J Clin Oncol. 2016;34(35):4261\u20134269.","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_3_4_241_1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh S","year":"2013","unstructured":"Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108(6):881\u2013891; quiz 892.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"e_1_3_4_242_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial","volume":"17","author":"Higurashi T","year":"2016","unstructured":"Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, Uchiyama T, Taniguchi L, Hata Y, Uchiyama S, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016;17(4):475\u2013483.","journal-title":"Lancet Oncol"},{"issue":"1","key":"e_1_3_4_243_1","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1186\/s12885-018-5126-7","article-title":"The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2\u2009\u00d7\u20092 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients","volume":"18","author":"Petrera M","year":"2018","unstructured":"Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mislej EM, Stabuc B, Gnant M, et al. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2\u2009\u00d7\u20092 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. BMC Cancer. 2018;18(1):1210.","journal-title":"BMC Cancer"},{"issue":"10105","key":"e_1_3_4_244_1","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker PM","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, CANTOS Trial Group. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833\u20131842.","journal-title":"Lancet"},{"issue":"6","key":"e_1_3_4_245_1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong DS","year":"2014","unstructured":"Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, et al. MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15(6):656\u2013666.","journal-title":"Lancet Oncol"},{"issue":"4","key":"e_1_3_4_246_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"14","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018;14(4):247\u2013249.","journal-title":"J Oncol Pract"},{"issue":"12","key":"e_1_3_4_247_1","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1200\/JCO.2005.04.2838","article-title":"Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients","volume":"24","author":"Monk JP","year":"2006","unstructured":"Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006;24(12):1852\u20131859.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_4_248_1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting interleukin-6 signaling in clinic","volume":"50","author":"Kang S","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007\u20131023.","journal-title":"Immunity"},{"issue":"10","key":"e_1_3_4_249_1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi D","year":"2018","unstructured":"Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A, et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer. 2018;119(10):1208\u20131214.","journal-title":"Br J Cancer"},{"issue":"4","key":"e_1_3_4_250_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle E","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity. 2019;50(4):924\u2013940.","journal-title":"Immunity"},{"issue":"6","key":"e_1_3_4_251_1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny B","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878\u2013885.","journal-title":"Nat Med"},{"issue":"4","key":"e_1_3_4_252_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients","volume":"29","author":"Halama N","year":"2016","unstructured":"Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell. 2016;29(4):587\u2013601.","journal-title":"Cancer Cell"},{"issue":"5","key":"e_1_3_4_253_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41568-019-0135-7","article-title":"Targeting cancer vulnerabilities with high-dose vitamin C","volume":"19","author":"Ngo B","year":"2019","unstructured":"Ngo B, Van Riper JM, Cantley LC, Yun J. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer. 2019;19(5):271\u2013282.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"e_1_3_4_254_1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ni.3754","article-title":"Nutrition, inflammation and cancer","volume":"18","author":"Zitvogel L","year":"2017","unstructured":"Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017;18(8):843\u2013850.","journal-title":"Nat Immunol"},{"issue":"5","key":"e_1_3_4_255_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3691","article-title":"The role of vitamin D in reducing cancer risk and progression","volume":"14","author":"Feldman D","year":"2014","unstructured":"Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342\u2013357.","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"e_1_3_4_256_1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/jama.2019.2210","article-title":"Effect of vitamin D supplementation on relapse-free survival among patients with digestive tract cancers: the AMATERASU randomized clinical trial","volume":"321","author":"Urashima M","year":"2019","unstructured":"Urashima M, Ohdaira H, Akutsu T, Okada S, Yoshida M, Kitajima M, Suzuki Y. Effect of vitamin D supplementation on relapse-free survival among patients with digestive tract cancers: the AMATERASU randomized clinical trial. JAMA. 2019;321(14):1361\u20131369.","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_4_257_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/jamaoncol.2019.4587","article-title":"Effect of supplementation with marine \u03c9-3 fatty acid on risk of colorectal adenomas and serrated polyps in the US general population: a prespecified ancillary study of a randomized clinical trial","volume":"6","author":"Song M","year":"2020","unstructured":"Song M, Lee IM, Manson JE, Buring JE, Dushkes R, Gordon D, Walter J, Wu K, Chan AT, Ogino S, et al. Effect of supplementation with marine \u03c9-3 fatty acid on risk of colorectal adenomas and serrated polyps in the US general population: a prespecified ancillary study of a randomized clinical trial. JAMA Oncol. 2020;6(1):108\u2013115.","journal-title":"JAMA Oncol"},{"issue":"10","key":"e_1_3_4_258_1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/jnci\/djs195","article-title":"Dietary supplements and cancer prevention: balancing potential benefits against proven harms","volume":"104","author":"Mart\u00ednez ME","year":"2012","unstructured":"Mart\u00ednez ME, Jacobs ET, Baron JA, Marshall JR, Byers T. Dietary supplements and cancer prevention: balancing potential benefits against proven harms. J Natl Cancer Inst. 2012;104(10):732\u2013739.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_4_259_1","first-page":"l5016","article-title":"Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial","volume":"366","author":"Li WQ","year":"2019","unstructured":"Li WQ, Zhang JY, Ma JL, Li ZX, Zhang L, Zhang Y, Guo Y, Zhou T, Li JY, Shen L, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ. 2019;366:l5016.","journal-title":"BMJ"},{"issue":"3","key":"e_1_3_4_260_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","article-title":"Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study","volume":"5","author":"Chen YX","year":"2020","unstructured":"Chen YX, Gao QY, Zou TH, Wang BM, Liu SD, Sheng JQ, Ren JL, Zou XP, Liu ZJ, Song YY, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267\u2013275.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"e_1_3_4_261_1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12967-025-06583-3","article-title":"Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches","volume":"23","author":"Bakrim S","year":"2025","unstructured":"Bakrim S, Fessikh ME, Elhrech H, Omari NE, Amanullah M, Ming LC, Moshawih S, Bouyahya A. Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches. J Transl Med. 2025;23(1):588.","journal-title":"J Transl Med"},{"issue":"4","key":"e_1_3_4_262_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5115\/acb.2017.50.4.293","article-title":"Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress","volume":"50","author":"Kim B","year":"2017","unstructured":"Kim B, Kim J, Kim YS. Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress. Anat Cell Biol. 2017;50(4):293\u2013300.","journal-title":"Anat Cell Biol"},{"issue":"3","key":"e_1_3_4_263_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.pan.2018.02.006","article-title":"Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3\/NF-kB and L1CAM activities","volume":"18","author":"Zuo C","year":"2018","unstructured":"Zuo C, Hong Y, Qiu X, Yang D, Liu N, Sheng X, Zhou K, Tang B, Xiong S, Ma M, et al. Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3\/NF-kB and L1CAM activities. Pancreatology. 2018;18(3):328\u2013333.","journal-title":"Pancreatology"},{"key":"e_1_3_4_264_1","doi-asserted-by":"crossref","first-page":"1691392","DOI":"10.3389\/fphar.2025.1691392","article-title":"Celecoxib in oncology: targeting the COX-2\/PGE2 axis to reprogram the tumor immune microenvironment and enhance multimodal therapy","volume":"16","author":"Kuang B","year":"2025","unstructured":"Kuang B, Yang K, Zhong X, Tan Y, Zhou Y, Ye J. Celecoxib in oncology: targeting the COX-2\/PGE2 axis to reprogram the tumor immune microenvironment and enhance multimodal therapy. Front Pharmacol. 2025;16:1691392.","journal-title":"Front Pharmacol"},{"issue":"9","key":"e_1_3_4_265_1","first-page":"551","article-title":"Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target","volume":"130","author":"Kim SH","year":"2004","unstructured":"Kim SH, Song SH, Kim SG, Chun KS, Lim SY, Na HK, Kim JW, Surh YJ, Bang YJ, Song YS. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol. 2004;130(9):551\u2013560.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"e_1_3_4_266_1","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/tox.23631","article-title":"Parecoxib expresses anti-metastasis effect through inhibition of epithelial-mesenchymal transition and the Wnt\/\u03b2-catenin signaling pathway in human colon cancer DLD-1 cell line","volume":"37","author":"Wong CH","year":"2022","unstructured":"Wong CH, Chang WL, Lu FJ, Liu YW, Peng JY, Chen CH. Parecoxib expresses anti-metastasis effect through inhibition of epithelial-mesenchymal transition and the Wnt\/\u03b2-catenin signaling pathway in human colon cancer DLD-1 cell line. Environ Toxicol. 2022;37(11):2718\u20132727.","journal-title":"Environ Toxicol"},{"issue":"2","key":"e_1_3_4_267_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10585-023-10199-6","article-title":"Sufentanil combined with parecoxib sodium inhibits proliferation and metastasis of HER2-positive breast cancer cells and regulates epithelial-mesenchymal transition","volume":"40","author":"Xu S","year":"2023","unstructured":"Xu S, Li X, Li W, Ma N, Ma H, Cui J, You X, Chen X. Sufentanil combined with parecoxib sodium inhibits proliferation and metastasis of HER2-positive breast cancer cells and regulates epithelial-mesenchymal transition. Clin Exp Metastasis. 2023;40(2):149\u2013160.","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"e_1_3_4_268_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S1091-255X(02)00061-6","article-title":"Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer","volume":"6","author":"Tseng WW","year":"2002","unstructured":"Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg. 2002;6(6):838\u2013843; discussion 844.","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"e_1_3_4_269_1","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.21037\/tlcr.2018.04.17","article-title":"COX-2 inhibitors in NSCLC: never-ending story or misplaced?","volume":"7","author":"Martinez-Marti A","year":"2018","unstructured":"Martinez-Marti A, Navarro A, Felip E. COX-2 inhibitors in NSCLC: never-ending story or misplaced? Transl Lung Cancer Res. 2018;7(Suppl 3):S191\u2013s194.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"e_1_3_4_270_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.sla.0000149427.84712.d9","article-title":"Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery","volume":"241","author":"Tanaka T","year":"2005","unstructured":"Tanaka T, Delong PA, Amin K, Henry A, Kruklitis R, Kapoor V, Kaiser LR, Albelda SM. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg. 2005;241(1):168\u2013178.","journal-title":"Ann Surg"},{"issue":"3","key":"e_1_3_4_271_1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0016-5085(03)01061-8","article-title":"The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases","volume":"125","author":"Fenwick SW","year":"2003","unstructured":"Fenwick SW, Toogood GJ, Lodge JPA, Hull MA. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology. 2003;125(3):716\u2013729.","journal-title":"Gastroenterology"},{"issue":"40","key":"e_1_3_4_272_1","doi-asserted-by":"crossref","first-page":"67670","DOI":"10.18632\/oncotarget.18802","article-title":"Dexamethasone affects cell growth\/apoptosis\/chemosensitivity of colon cancer via glucocorticoid receptor \u03b1\/NF-\u03baB","volume":"8","author":"He J","year":"2017","unstructured":"He J, Zhou J, Yang W, Zhou Q, Liang X, Pang X, Li J, Pan F, Liang H. Dexamethasone affects cell growth\/apoptosis\/chemosensitivity of colon cancer via glucocorticoid receptor \u03b1\/NF-\u03baB. Oncotarget. 2017;8(40):67670\u201367683.","journal-title":"Oncotarget"},{"issue":"2","key":"e_1_3_4_273_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/aja202155","article-title":"Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this \u201ccort\u201d is not out of order!","volume":"24","author":"Van Praet C","year":"2022","unstructured":"Van Praet C, Fonteyne V, Lumen N. Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this \u201ccort\u201d is not out of order!. Asian J Androl. 2022;24(2):225.","journal-title":"Asian J Androl"},{"issue":"5","key":"e_1_3_4_274_1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun MJ","year":"2012","unstructured":"Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259\u2013267.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"e_1_3_4_275_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3748\/wjg.v11.i3.340","article-title":"Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo","volume":"11","author":"Wang HM","year":"2005","unstructured":"Wang HM, Zhang GY. Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo. World J Gastroenterol. 2005;11(3):340\u2013343.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"e_1_3_4_276_1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s10495-014-1002-3","article-title":"Indomethacin promotes apoptosis in gastric cancer cells through concomitant degradation of survivin and aurora B kinase proteins","volume":"19","author":"Chiou SK","year":"2014","unstructured":"Chiou SK, Hoa N, Hodges A, Ge L, Jadus MR. Indomethacin promotes apoptosis in gastric cancer cells through concomitant degradation of survivin and aurora B kinase proteins. Apoptosis. 2014;19(9):1378\u20131388.","journal-title":"Apoptosis"},{"key":"e_1_3_4_277_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3389\/fimmu.2016.00379","article-title":"Indomethacin treatment of mice with premalignant oral lesions sustains cytokine production and slows progression to cancer","volume":"7","author":"Johnson SD","year":"2016","unstructured":"Johnson SD, Young MR. Indomethacin treatment of mice with premalignant oral lesions sustains cytokine production and slows progression to cancer. Front Immunol. 2016;7:379.","journal-title":"Front Immunol"},{"issue":"20","key":"e_1_3_4_278_1","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/j.febslet.2005.06.049","article-title":"Diclofenac attenuates Wnt\/\u03b2-catenin signaling in colon cancer cells by activation of NF-\u03baB","volume":"579","author":"Cho M","year":"2005","unstructured":"Cho M, Gwak J, Park S, Won J, Kim D-E, Yea SS, Cha I-J, Kim TK, Shin J-G, Oh S. Diclofenac attenuates Wnt\/\u03b2-catenin signaling in colon cancer cells by activation of NF-\u03baB. FEBS Lett. 2005;579(20):4213\u20134218.","journal-title":"FEBS Lett"},{"key":"e_1_3_4_279_1","first-page":"610","article-title":"Repurposing drugs in oncology (ReDO)-diclofenac as an anti-cancer agent","volume":"10","author":"Pantziarka P","year":"2016","unstructured":"Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing drugs in oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience. 2016;10:610.","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"e_1_3_4_280_1","doi-asserted-by":"crossref","first-page":"e23203","DOI":"10.1016\/j.heliyon.2023.e23203","article-title":"The relationship between nonsteroidal anti-inflammatory drugs and cancer incidence: an umbrella review","volume":"10","author":"Wang P","year":"2024","unstructured":"Wang P, Chen B, Huang Y, Li J, Cao D, Chen Z, Li J, Ran B, Yang J, Wang R, et al. The relationship between nonsteroidal anti-inflammatory drugs and cancer incidence: an umbrella review. Heliyon. 2024;10(2):e23203.","journal-title":"Heliyon"},{"issue":"1","key":"e_1_3_4_281_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11033-022-07921-0","article-title":"Ketoprofen suppresses triple negative breast cancer cell growth by inducing apoptosis and inhibiting autophagy","volume":"50","author":"Patra I","year":"2023","unstructured":"Patra I, Naser RH, Hussam F, Hameed NM, Kadhim MM, Ahmad I, Awadh SA, Hamad DA, Parra RMR, Mustafa YF. Ketoprofen suppresses triple negative breast cancer cell growth by inducing apoptosis and inhibiting autophagy. Mol Biol Rep. 2023;50(1):85\u201395.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"e_1_3_4_282_1","doi-asserted-by":"crossref","first-page":"8824","DOI":"10.1021\/acsomega.9b00412","article-title":"Carboranyl analogues of ketoprofen with cytostatic activity against human melanoma and colon cancer cell lines","volume":"4","author":"Buzharevski A","year":"2019","unstructured":"Buzharevski A, Paskas S, Laube M, L\u00f6nnecke P, Neumann W, Murganic B, Mijatovic S, Maksimovic-Ivanic D, Pietzsch J, Hey-Hawkins E. Carboranyl analogues of ketoprofen with cytostatic activity against human melanoma and colon cancer cell lines. ACS Omega. 2019;4(5):8824\u20138833.","journal-title":"ACS Omega"},{"issue":"1","key":"e_1_3_4_283_1","doi-asserted-by":"crossref","first-page":"e136131","DOI":"10.5812\/ijpr-136131","article-title":"Co-treatment of naringenin and ketoprofen-RGD suppresses cell proliferation via calmodulin\/PDE\/cAMP\/PKA axis pathway in leukemia and ovarian cancer cells","volume":"22","author":"Afshari H","year":"2023","unstructured":"Afshari H, Noori S, Shokri B, Zarghi A. Co-treatment of naringenin and ketoprofen-RGD suppresses cell proliferation via calmodulin\/PDE\/cAMP\/PKA axis pathway in leukemia and ovarian cancer cells. Iran J Pharm Res. 2023;22(1):e136131.","journal-title":"Iran J Pharm Res"},{"issue":"3","key":"e_1_3_4_284_1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1532-5415.2004.52125_6.x","article-title":"Loxoprofen sodium and survival in older people with advanced non-small cell lung cancer","volume":"52","author":"Kanda A","year":"2004","unstructured":"Kanda A, Ebihara S, Okazaki T, Yasuda H, Sasaki H. Loxoprofen sodium and survival in older people with advanced non-small cell lung cancer. J Am Geriatr Soc. 2004;52(3):471\u2013472.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"e_1_3_4_285_1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/1940-6207.CAPR-13-0288","article-title":"Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K","volume":"7","author":"Kim MS","year":"2014","unstructured":"Kim MS, Kim JE, Lim DY, Huang Z, Chen H, Langfald A, Lubet RA, Grubbs CJ, Dong Z, Bode AM. Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K. Cancer Prev Res (Phila). 2014;7(2):236\u2013245.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"54","key":"e_1_3_4_286_1","doi-asserted-by":"crossref","first-page":"40031","DOI":"10.1039\/D4RA07581A","article-title":"Repurposing of indomethacin and naproxen as anticancer agents: progress from 2017 to present","volume":"14","author":"Kassab AE","year":"2024","unstructured":"Kassab AE, Gedawy EM. Repurposing of indomethacin and naproxen as anticancer agents: progress from 2017 to present. RSC Adv. 2024;14(54):40031\u201340057.","journal-title":"RSC Adv"},{"issue":"5","key":"e_1_3_4_287_1","first-page":"7191","article-title":"Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells","volume":"15","author":"Zhong J","year":"2018","unstructured":"Zhong J, Yu X, Dong X, Lu H, Zhou W, Li L, Li Z, Sun P, Shi X. Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells. Oncol Lett. 2018;15(5):7191\u20137199.","journal-title":"Oncol Lett"},{"issue":"12","key":"e_1_3_4_288_1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/carcin\/19.12.2195","article-title":"Meloxicam inhibits the growth of colorectal cancer cells","volume":"19","author":"Goldman AP","year":"1998","unstructured":"Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, DuBois RN. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis. 1998;19(12):2195\u20132199.","journal-title":"Carcinogenesis"},{"issue":"12","key":"e_1_3_4_289_1","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/j.1440-1746.2006.04366.x","article-title":"Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells","volume":"21","author":"Li J","year":"2006","unstructured":"Li J, Chen X, Dong X, Xu Z, Jiang H, Sun X. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. J Gastroenterol Hepatol. 2006;21(12):1814\u20131820.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"e_1_3_4_290_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2009.11.036","article-title":"Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system","volume":"387","author":"Montejo C","year":"2010","unstructured":"Montejo C, Barcia E, Negro S, Fern\u00e1ndez-Carballido A. Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system. Int J Pharm. 2010;387(1-2):223\u2013229.","journal-title":"Int J Pharm"},{"key":"e_1_3_4_291_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/jcb.240501330","article-title":"Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention","volume":"16","author":"Earnest DL","year":"1992","unstructured":"Earnest DL, Hixson LJ, Alberts DS. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J Cell Biochem Suppl. 1992;16i:156\u2013166.","journal-title":"J Cell Biochem Suppl"},{"issue":"5","key":"e_1_3_4_292_1","first-page":"4535","article-title":"Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy","volume":"13","author":"Melnikov V","year":"2021","unstructured":"Melnikov V, Tiburcio-Jimenez D, Mendoza-Hernandez MA, Delgado-Enciso J, De-Leon-Zaragoza L, Guzman-Esquivel J, Rodriguez-Sanchez IP, Martinez-Fierro ML, Lara-Esqueda A, Delgado-Enciso OG, et al. Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy. Am J Transl Res. 2021;13(5):4535\u20134543.","journal-title":"Am J Transl Res"},{"issue":"2","key":"e_1_3_4_293_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12032-021-01618-3","article-title":"Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice","volume":"39","author":"Seyyedi R","year":"2022","unstructured":"Seyyedi R, Talebpour Amiri F, Farzipour S, Mihandoust E, Hosseinimehr SJ. Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice. Med Oncol. 2022;39(2):18.","journal-title":"Med Oncol"},{"issue":"8","key":"e_1_3_4_294_1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2174\/1871520620666200415100614","article-title":"Anticancer potential of mefenamic acid derivatives with platelet-derived growth factor inhibitory property","volume":"20","author":"Patel SS","year":"2020","unstructured":"Patel SS, Tripathi R, Chavda VK, Savjani JK. Anticancer potential of mefenamic acid derivatives with platelet-derived growth factor inhibitory property. Anticancer Agents Med Chem. 2020;20(8):998\u20131008.","journal-title":"Anticancer Agents Med Chem"},{"issue":"5","key":"e_1_3_4_295_1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/ijc.23218","article-title":"Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells","volume":"122","author":"Ciolino HP","year":"2008","unstructured":"Ciolino HP, Bass SE, MacDonald CJ, Cheng RY, Yeh GC. Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008;122(5):990\u2013998.","journal-title":"Int J Cancer"},{"key":"e_1_3_4_296_1","unstructured":"Rahman MA Dhar DK Masunaga R Yamanoi A Kohno H Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. 2000;60(8):2085\u20132089. Cancer Res"},{"issue":"6","key":"e_1_3_4_297_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3748\/wjg.v7.i6.796","article-title":"Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells","volume":"7","author":"Wu YL","year":"2001","unstructured":"Wu YL, Sun B, Zhang XJ, Wang SN, He HY, Qiao MM, Zhong J, Xu JY. Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. World J Gastroenterol. 2001;7(6):796\u2013800.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"e_1_3_4_298_1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11255-011-0012-0","article-title":"Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation","volume":"44","author":"Soriano-Hern\u00e1ndez AD","year":"2012","unstructured":"Soriano-Hern\u00e1ndez AD, Galvan-Salazar HR, Montes-Galindo DA, Rodriguez-Hernandez A, Martinez-Martinez R, Guzman-Esquivel J, Valdez-Velazquez LL, Baltazar-Rodriguez LM, Espinoza-G\u00f3mez F, Rojas-Martinez A, et al. Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation. Int Urol Nephrol. 2012;44(2):471\u2013477.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"e_1_3_4_299_1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3748\/wjg.v9.i5.915","article-title":"Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line","volume":"9","author":"Li JY","year":"2003","unstructured":"Li JY, Wang XZ, Chen FL, Yu JP, Luo HS. Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol. 2003;9(5):915\u2013920.","journal-title":"World J Gastroenterol"},{"issue":"20","key":"e_1_3_4_300_1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.3748\/wjg.v13.i20.2872","article-title":"5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro","volume":"13","author":"Fang HM","year":"2007","unstructured":"Fang HM, Mei Q, Xu JM, Ma WJ. 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. World J Gastroenterol. 2007;13(20):2872\u20132877.","journal-title":"World J Gastroenterol"},{"key":"e_1_3_4_301_1","doi-asserted-by":"crossref","first-page":"108850","DOI":"10.1016\/j.bioorg.2025.108850","article-title":"Investigation of novel nimesulide derivatives against breast cancer","volume":"164","author":"Birg\u00fcl K","year":"2025","unstructured":"Birg\u00fcl K, Atl\u0131han \u0130, Dere D, Yelek\u00e7i K, Tiber PM, Orun O, K\u00fc\u00e7\u00fckg\u00fczel \u015eG. Investigation of novel nimesulide derivatives against breast cancer. Bioorg Chem. 2025;164:108850.","journal-title":"Bioorg Chem"},{"issue":"2","key":"e_1_3_4_302_1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12032-007-9016-0","article-title":"Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo","volume":"25","author":"Li W","year":"2008","unstructured":"Li W, Zhang HH, Xu RJ, Zhuo GC, Hu YQ, Li J. Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo. Med Oncol. 2008;25(2):172\u2013177.","journal-title":"Med Oncol"},{"issue":"10","key":"e_1_3_4_303_1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1054\/bjoc.2001.1807","article-title":"Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation","volume":"84","author":"Roy H","year":"2001","unstructured":"Roy H, Karoski W, Ratashak A, Smyrk T. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation. Br J Cancer. 2001;84(10):1412\u20131416.","journal-title":"Br J Cancer"},{"issue":"3","key":"e_1_3_4_304_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.humimm.2009.12.010","article-title":"Improvement of dendritic-based vaccine efficacy against hepatitis B virus\u2013related hepatocellular carcinoma by two tumor-associated antigen gene\u2013infected dendritic cells","volume":"71","author":"Yang J-Y","year":"2010","unstructured":"Yang J-Y, Cao D-Y, Xue Y, Yu Z-C, Liu W-C. Improvement of dendritic-based vaccine efficacy against hepatitis B virus\u2013related hepatocellular carcinoma by two tumor-associated antigen gene\u2013infected dendritic cells. Hum Immunol. 2010;71(3):255\u2013262.","journal-title":"Hum Immunol"},{"issue":"2","key":"e_1_3_4_305_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","article-title":"Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B","volume":"38","author":"Singal A","year":"2013","unstructured":"Singal A, Salameh H, Kuo YF, Fontana R. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2013;38(2):98\u2013106.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"e_1_3_4_306_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3851\/IMP3372","article-title":"Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside\/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study","volume":"25","author":"Jia J","year":"2020","unstructured":"Jia J, Shang J, Tang H, Jiang J, Ning Q, Dou X, Zhang S, Zhang M, Han T, Tan D, EVOLVE Study Group, et al. Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside\/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study. Antivir Ther. 2020;25(6):293\u2013304.","journal-title":"Antivir Ther"},{"issue":"9","key":"e_1_3_4_307_1","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/bcp.70113","article-title":"Approaches to repurposing reverse transcriptase antivirals in cancer","volume":"91","author":"Head R","year":"2025","unstructured":"Head R, Islam S, Martin JH. Approaches to repurposing reverse transcriptase antivirals in cancer. Br J Clin Pharmacol. 2025;91(9):2494\u20132506.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"e_1_3_4_308_1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-18-0666","article-title":"The use of ribavirin as an anticancer therapeutic: will it go viral?","volume":"18","author":"Casaos J","year":"2019","unstructured":"Casaos J, Gorelick NL, Huq S, Choi J, Xia Y, Serra R, Felder R, Lott T, Kast RE, Suk I, et al. The use of ribavirin as an anticancer therapeutic: will it go viral? Mol Cancer Ther. 2019;18(7):1185\u20131194.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"e_1_3_4_309_1","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3892\/or.2015.3816","article-title":"Ribavirin as a tri-targeted antitumor repositioned drug","volume":"33","author":"De la Cruz-Hernandez E","year":"2015","unstructured":"De la Cruz-Hernandez E, Medina-Franco JL, Trujillo J, Chavez-Blanco A, Dominguez-Gomez G, Perez-Cardenas E, Gonzalez-Fierro A, Taja-Chayeb L, Due\u00f1as-Gonzalez A. Ribavirin as a tri-targeted antitumor repositioned drug. Oncol Rep. 2015;33(5):2384\u20132392.","journal-title":"Oncol Rep"},{"issue":"11","key":"e_1_3_4_310_1","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40265-014-0255-z","article-title":"Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil\u00ae): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts","volume":"74","author":"McCormack PL.","year":"2014","unstructured":"McCormack PL. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil\u00ae): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs. 2014;74(11):1253\u20131283.","journal-title":"Drugs"},{"issue":"2","key":"e_1_3_4_311_1","doi-asserted-by":"crossref","first-page":"e004232","DOI":"10.1136\/jitc-2021-004232","article-title":"ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response","volume":"10","author":"Sousa LGd","year":"2022","unstructured":"Sousa LGd, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, William W, Johnson FM, et al. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022;10(2):e004232.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_312_1","doi-asserted-by":"crossref","first-page":"102715","DOI":"10.1016\/j.tranon.2026.102715","article-title":"Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation","volume":"67","author":"Filippini DM","year":"2026","unstructured":"Filippini DM, Le Tourneau C. Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation. Transl Oncol. 2026;67:102715.","journal-title":"Transl Oncol"},{"issue":"1","key":"e_1_3_4_313_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-18-1763","article-title":"Immunotherapy targeting HPV16\/18 generates potent immune responses in HPV-associated head and neck cancer","volume":"25","author":"Aggarwal C","year":"2019","unstructured":"Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, et al. Immunotherapy targeting HPV16\/18 generates potent immune responses in HPV-associated head and neck cancer. Clin Cancer Res. 2019;25(1):110\u2013124.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"e_1_3_4_314_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/vaccines10010053","article-title":"The efficacy of therapeutic DNA vaccines expressing the human papillomavirus E6 and E7 oncoproteins for treatment of cervical cancer: systematic review","volume":"10","author":"Akhatova A","year":"2021","unstructured":"Akhatova A, Chan CK, Azizan A, Aimagambetova G. The efficacy of therapeutic DNA vaccines expressing the human papillomavirus E6 and E7 oncoproteins for treatment of cervical cancer: systematic review. Vaccines (Basel). 2021;10(1):53.","journal-title":"Vaccines (Basel)"},{"issue":"22","key":"e_1_3_4_315_1","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-12-0896","article-title":"Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor","volume":"18","author":"Dosset M","year":"2012","unstructured":"Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, et al. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res. 2012;18(22):6284\u20136295.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"e_1_3_4_316_1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12935-024-03624-7","article-title":"Telomerase-based vaccines: a promising frontier in cancer immunotherapy","volume":"24","author":"Vahidi S","year":"2024","unstructured":"Vahidi S, Zabeti Touchaei A. Telomerase-based vaccines: a promising frontier in cancer immunotherapy. Cancer Cell Int. 2024;24(1):421.","journal-title":"Cancer Cell Int"},{"key":"e_1_3_4_317_1","doi-asserted-by":"crossref","first-page":"111858","DOI":"10.1016\/j.biopha.2021.111858","article-title":"The potential use of simvastatin for cancer treatment: a review","volume":"141","author":"Duarte JA","year":"2021","unstructured":"Duarte JA, de Barros ALB, Leite EA. The potential use of simvastatin for cancer treatment: a review. Biomed Pharmacother. 2021;141:111858.","journal-title":"Biomed Pharmacother"},{"key":"e_1_3_4_318_1","doi-asserted-by":"crossref","first-page":"151078","DOI":"10.1016\/j.bbrc.2024.151078","article-title":"Synergistic antitumor effects of atorvastatin and chemotherapies: in vitro and in vivo studies","volume":"742","author":"El-Said KS","year":"2025","unstructured":"El-Said KS, Attia MS, Abdelmoaty BE, Salim EI. Synergistic antitumor effects of atorvastatin and chemotherapies: in vitro and in vivo studies. Biochem Biophys Res Commun. 2025;742:151078.","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_4_319_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2023.41.4_suppl.131","article-title":"Phase II trial of rosuvastatin combined with chemoradiation therapy (CRT) in the treatment of high-risk locally advanced rectal cancer (STARC trial)","volume":"41","author":"Monzon JG","year":"2023","unstructured":"Monzon JG, Joseph K, Chen EX, Tang PA, Sinha R, Dennis K, Goodwin RA, Severin D, Dimitroulakos J, Vickers MM. Phase II trial of rosuvastatin combined with chemoradiation therapy (CRT) in the treatment of high-risk locally advanced rectal cancer (STARC trial). J Clin Oncol. 2023;41:131.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_320_1","doi-asserted-by":"crossref","first-page":"102068","DOI":"10.1016\/j.mcp.2026.102068","article-title":"Metformin and oncogenic pathways: crosstalk between energy sensing and tumor progression","volume":"86","author":"Zhang Y","year":"2026","unstructured":"Zhang Y, Zhao L, Zhang K, Gao Y. Metformin and oncogenic pathways: crosstalk between energy sensing and tumor progression. Mol Cell Probes. 2026;86:102068.","journal-title":"Mol Cell Probes"},{"key":"e_1_3_4_321_1","doi-asserted-by":"crossref","first-page":"122276","DOI":"10.1016\/j.lfs.2023.122276","article-title":"Interleukin-1 receptor antagonist: an alternative therapy for cancer treatment","volume":"335","author":"Fang Z","year":"2023","unstructured":"Fang Z, Jiang J, Zheng X. Interleukin-1 receptor antagonist: an alternative therapy for cancer treatment. Life Sci. 2023;335:122276.","journal-title":"Life Sci"},{"issue":"6","key":"e_1_3_4_322_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/2326-6066.CIR-22-0290","article-title":"Targeting the IL1\u03b2 pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses","volume":"11","author":"Diwanji R","year":"2023","unstructured":"Diwanji R, O\u2019Brien NA, Choi JE, Nguyen B, Laszewski T, Grauel AL, Yan Z, Xu X, Wu J, Ruddy DA, et al. Targeting the IL1\u03b2 pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses. Cancer Immunol Res. 2023;11(6):777\u2013791.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"e_1_3_4_323_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1479-5876-4-48","article-title":"Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment","volume":"4","author":"Lewis AM","year":"2006","unstructured":"Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 2006;4(1):48.","journal-title":"J Transl Med"},{"key":"e_1_3_4_324_1","doi-asserted-by":"crossref","first-page":"111251","DOI":"10.1016\/j.jbc.2026.111251","article-title":"TNF-alpha: roles in pathogenesis and therapeutics in cancer","volume":"302","author":"Valenzuela-Cardenas M","year":"2026","unstructured":"Valenzuela-Cardenas M, Nowicki T. TNF-alpha: roles in pathogenesis and therapeutics in cancer. J Biol Chem. 2026;302:111251.","journal-title":"J Biol Chem"},{"issue":"12","key":"e_1_3_4_325_1","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/jcpt.13781","article-title":"Evaluation of the Tocilizumab therapy in human cancers: latest evidence and clinical potential","volume":"47","author":"Ghasemi K","year":"2022","unstructured":"Ghasemi K, Ghasemi K. Evaluation of the Tocilizumab therapy in human cancers: latest evidence and clinical potential. J Clin Pharm Ther. 2022;47(12):2360\u20132368.","journal-title":"J Clin Pharm Ther"},{"key":"e_1_3_4_326_1","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.2147\/DDDT.S86438","article-title":"Siltuximab (CNTO 328): a promising option for human malignancies","volume":"9","author":"Chen R","year":"2015","unstructured":"Chen R, Chen B. Siltuximab (CNTO 328): a promising option for human malignancies. Drug Des Devel Ther. 2015;9:3455\u20133458.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"e_1_3_4_327_1","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.18632\/oncotarget.23795","article-title":"Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-\u03b2 receptor type I inhibitor","volume":"9","author":"Yingling JM","year":"2018","unstructured":"Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-\u03b2 receptor type I inhibitor. Oncotarget. 2018;9(6):6659\u20136677.","journal-title":"Oncotarget"},{"key":"e_1_3_4_328_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41419-026-08581-9","article-title":"The TGF-\u03b2R1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization","volume":"17","author":"Cucchiara M","year":"2026","unstructured":"Cucchiara M, Palano MT, Rubuano C, De Antoni G, Gallazzi M, Mercatelli D, Tagliabue M, Pessi A, Catalano G, Gemelli M, et al. The TGF-\u03b2R1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization. Cell Death Dis. 2026;17:577.","journal-title":"Cell Death Dis"},{"issue":"1","key":"e_1_3_4_329_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-\u03b2 pathway","volume":"14","author":"Kim B-G","year":"2021","unstructured":"Kim B-G, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-\u03b2 pathway. J Hematol Oncol. 2021;14(1):55.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"e_1_3_4_330_1","doi-asserted-by":"crossref","first-page":"114884","DOI":"10.1016\/j.ejmech.2022.114884","article-title":"CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment","volume":"245","author":"Wen J","year":"2023","unstructured":"Wen J, Wang S, Guo R, Liu D. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. Eur J Med Chem. 2023;245(Pt 1):114884.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"e_1_3_4_331_1","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/acsmedchemlett.1c00373","article-title":"BMS-813160: a potent CCR2 and CCR5 dual antagonist selected as a clinical candidate","volume":"12","author":"Cherney RJ","year":"2021","unstructured":"Cherney RJ, Anjanappa P, Selvakumar K, Batt DG, Brown GD, Rose AV, Vuppugalla R, Chen J, Pang J, Xu S, et al. BMS-813160: a potent CCR2 and CCR5 dual antagonist selected as a clinical candidate. ACS Med Chem Lett. 2021;12(11):1753\u20131758.","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"e_1_3_4_332_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14728222.2021.1902505","article-title":"CCR5 is a potential therapeutic target for cancer","volume":"25","author":"Hemmatazad H","year":"2021","unstructured":"Hemmatazad H, Berger MD. CCR5 is a potential therapeutic target for cancer. Expert Opin Ther Targets. 2021;25(4):311\u2013327.","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"e_1_3_4_333_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2326-6066.CIR-20-0312","article-title":"Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity","volume":"9","author":"Yang J","year":"2021","unstructured":"Yang J, Yan C, Vilgelm AE, Chen S-C, Ayers GD, Johnson CA, Richmond A. Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity. Cancer Immunol Res. 2021;9(2):200\u2013213.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"e_1_3_4_334_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/13543776.2025.2462848","article-title":"Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024","volume":"35","author":"Sahin Z","year":"2025","unstructured":"Sahin Z, Tahirovic YA, Geng J, Wilson LJ, Liotta DC. Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024. Expert Opin Ther Pat. 2025;35(4):357\u2013369.","journal-title":"Expert Opin Ther Pat"},{"key":"e_1_3_4_335_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.semcancer.2020.05.018","article-title":"An update on vitamin D signaling and cancer","volume":"79","author":"Carlberg C","year":"2022","unstructured":"Carlberg C, Mu\u00f1oz A. An update on vitamin D signaling and cancer. Semin Cancer Biol. 2022;79:217\u2013230.","journal-title":"Semin Cancer Biol"},{"key":"e_1_3_4_336_1","doi-asserted-by":"crossref","first-page":"110265","DOI":"10.1016\/j.jnutbio.2026.110265","article-title":"Vitamin E and related tocols in cancer: unraveling the paradox of antioxidant and pro-oxidant roles","volume":"151","author":"Xiao F","year":"2026","unstructured":"Xiao F, Wang Z-B, Wu N, Zhang X, Yu X, He Z-P, Wang J. Vitamin E and related tocols in cancer: unraveling the paradox of antioxidant and pro-oxidant roles. J Nutr Biochem. 2026;151:110265.","journal-title":"J Nutr Biochem"},{"issue":"3","key":"e_1_3_4_337_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10555-015-9572-2","article-title":"Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials","volume":"34","author":"Nabavi SF","year":"2015","unstructured":"Nabavi SF, Bilotto S, Russo GL, Orhan IE, Habtemariam S, Daglia M, Devi KP, Loizzo MR, Tundis R, Nabavi SM. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. Cancer Metastasis Rev. 2015;34(3):359\u2013380.","journal-title":"Cancer Metastasis Rev"},{"key":"e_1_3_4_338_1","doi-asserted-by":"crossref","first-page":"1695200","DOI":"10.3389\/fphar.2025.1695200","article-title":"Curcumin: biochemistry, pharmacology, advanced drug delivery systems, and its epigenetic role in combating cancer","volume":"16","author":"Smail SW","year":"2025","unstructured":"Smail SW, Bergsten P, Taha KO, Yashooa RK, Hawezy DJ, Abbas MA, Shekha MS. Curcumin: biochemistry, pharmacology, advanced drug delivery systems, and its epigenetic role in combating cancer. Front Pharmacol. 2025;16:1695200.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_339_1","doi-asserted-by":"crossref","first-page":"107742","DOI":"10.1016\/j.phrs.2025.107742","article-title":"Coptidis rhizoma and berberine as anti-cancer drugs: a 10-year updates and future perspectives","volume":"216","author":"Chen G","year":"2025","unstructured":"Chen G, Zhang C, Zou J, Zhou Z, Zhang J, Yan Y, Liang Y, Tang G, Chen G, Xu X, et al. Coptidis rhizoma and berberine as anti-cancer drugs: a 10-year updates and future perspectives. Pharmacol Res. 2025;216:107742.","journal-title":"Pharmacol Res"},{"key":"e_1_3_4_340_1","doi-asserted-by":"crossref","first-page":"105837","DOI":"10.1016\/j.phrs.2021.105837","article-title":"Garlic constituents for cancer prevention and therapy: from phytochemistry to novel formulations","volume":"175","author":"Mondal A","year":"2022","unstructured":"Mondal A, Banerjee S, Bose S, Mazumder S, Haber RA, Farzaei MH, Bishayee A. Garlic constituents for cancer prevention and therapy: from phytochemistry to novel formulations. Pharmacol Res. 2022;175:105837.","journal-title":"Pharmacol Res"},{"issue":"24","key":"e_1_3_4_341_1","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.8b01424","article-title":"Discovery of nonquinone substrates for NAD (P) H: quinone oxidoreductase 1 (NQO1) as effective intracellular ROS generators for the treatment of drug-resistant non-small-cell lung cancer","volume":"61","author":"Wu X","year":"2018","unstructured":"Wu X, Li X, Li Z, Yu Y, You Q, Zhang X. Discovery of nonquinone substrates for NAD (P) H: quinone oxidoreductase 1 (NQO1) as effective intracellular ROS generators for the treatment of drug-resistant non-small-cell lung cancer. J Med Chem. 2018;61(24):11280\u201311297.","journal-title":"J Med Chem"},{"issue":"7","key":"e_1_3_4_342_1","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1021\/acs.jmedchem.2c02036","article-title":"Novel indole\u2013chalcone derivative-ligated platinum (IV) prodrugs attenuate cisplatin resistance in lung cancer through ROS\/ER stress and mitochondrial dysfunction","volume":"66","author":"Liu Z","year":"2023","unstructured":"Liu Z, Wang M, Huang R, Hu T, Jing Y, Huang X, Hu W, Cao G, Wang H. Novel indole\u2013chalcone derivative-ligated platinum (IV) prodrugs attenuate cisplatin resistance in lung cancer through ROS\/ER stress and mitochondrial dysfunction. J Med Chem. 2023;66(7):4868\u20134887.","journal-title":"J Med Chem"},{"issue":"1","key":"e_1_3_4_343_1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/acs.molpharmaceut.2c00885","article-title":"Synthesis of novel pentacyclic triterpenoid derivatives that induce apoptosis in cancer cells through a ROS-dependent, mitochondrial-mediated pathway","volume":"20","author":"Cheng B","year":"2023","unstructured":"Cheng B, Chu X, Liu R, Ma X, Wang M, Zhang J, Jiao P, Gao Q, Ma W, Zhang Y, et al. Synthesis of novel pentacyclic triterpenoid derivatives that induce apoptosis in cancer cells through a ROS-dependent, mitochondrial-mediated pathway. Mol Pharm. 2023;20(1):701\u2013710.","journal-title":"Mol Pharm"},{"key":"e_1_3_4_344_1","doi-asserted-by":"crossref","first-page":"118772","DOI":"10.1016\/j.ejmech.2026.118772","article-title":"Novel nitric oxide-releasing triptolidenol derivatives suppress gastric cancer by targeting the folate one-carbon metabolism pathway and inducing ROS accumulation","volume":"309","author":"Tian Y","year":"2026","unstructured":"Tian Y, Guan J, Luo H, Ning Q, Yang X, Ma J, Zang Y, Li C, Lai F, Zhang D. Novel nitric oxide-releasing triptolidenol derivatives suppress gastric cancer by targeting the folate one-carbon metabolism pathway and inducing ROS accumulation. Eur J Med Chem. 2026;309:118772.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"e_1_3_4_345_1","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/acs.jmedchem.5c00038","article-title":"Bisboronic ester-enabled redox-targeted cancer therapy: a cascade ROS consumption approach for efficient elimination of cancer cells","volume":"68","author":"Huang S","year":"2025","unstructured":"Huang S, Cui Y, Wang B, Liu F-J, Liu J-Y, Shao W, Wang X-Q, Guo Q. Bisboronic ester-enabled redox-targeted cancer therapy: a cascade ROS consumption approach for efficient elimination of cancer cells. J Med Chem. 2025;68(6):6656\u20136664.","journal-title":"J Med Chem"},{"issue":"12","key":"e_1_3_4_346_1","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1021\/acs.jmedchem.3c00063","article-title":"NSAID\u2013Au (I) complexes induce ROS-driven DAMPs and interpose inflammation to stimulate the immune response against ovarian cancer","volume":"66","author":"Xu Z","year":"2023","unstructured":"Xu Z, Lu Q, Shan M, Jiang G, Liu Y, Yang Z, Lu Y, Liu W. NSAID\u2013Au (I) complexes induce ROS-driven DAMPs and interpose inflammation to stimulate the immune response against ovarian cancer. J Med Chem. 2023;66(12):7813\u20137833.","journal-title":"J Med Chem"},{"key":"e_1_3_4_347_1","doi-asserted-by":"crossref","first-page":"113475","DOI":"10.1016\/j.ejmech.2021.113475","article-title":"Beyond direct Nrf2 activation; reinvestigating 1, 2, 4-oxadiazole scaffold as a master key unlocking the antioxidant cellular machinery for cancer therapy","volume":"220","author":"Ayoup MS","year":"2021","unstructured":"Ayoup MS, Abu-Serie MM, Abdel-Hamid H, Teleb M. Beyond direct Nrf2 activation; reinvestigating 1, 2, 4-oxadiazole scaffold as a master key unlocking the antioxidant cellular machinery for cancer therapy. Eur J Med Chem. 2021;220:113475.","journal-title":"Eur J Med Chem"},{"issue":"23","key":"e_1_3_4_348_1","doi-asserted-by":"crossref","first-page":"24986","DOI":"10.1021\/acs.jmedchem.5c01938","article-title":"Discovery and Structural Optimization of Novel 2-Aminopyrimidine Derivatives as Potent and Selective IKK\u03b2 Inhibitors for the Treatment of Colorectal Cancer","volume":"68","author":"Wang K","year":"2025","unstructured":"Wang K, Hu Y, Liu P, Shi C, Yuan J, Zang Y, He Y, Li B, Zheng J, Tong J, et al. Discovery and Structural Optimization of Novel 2-Aminopyrimidine Derivatives as Potent and Selective IKK\u03b2 Inhibitors for the Treatment of Colorectal Cancer. J Med Chem. 2025;68(23):24986\u201325010.","journal-title":"J Med Chem"},{"issue":"1","key":"e_1_3_4_349_1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1080\/14756366.2021.1953996","article-title":"Trifluoromethyl-substituted 3, 5-bis (arylidene)-4-piperidones as potential anti-hepatoma and anti-inflammation agents by inhibiting NF-\u043aB activation","volume":"36","author":"Cong W","year":"2021","unstructured":"Cong W, Sun Y, Sun Y-F, Yan W-B, Zhang Y-L, Gao Z-F, Wang C-H, Hou G-G, Zhang J-J. Trifluoromethyl-substituted 3, 5-bis (arylidene)-4-piperidones as potential anti-hepatoma and anti-inflammation agents by inhibiting NF-\u043aB activation. J Enzyme Inhib Med Chem. 2021;36(1):1622\u20131631.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"4","key":"e_1_3_4_350_1","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ymthe.2025.01.048","article-title":"Development of RelB-targeting small-molecule inhibitors of non-canonical NF-\u03baB signaling with antitumor efficacy","volume":"33","author":"Li C","year":"2025","unstructured":"Li C, Wei S, Sun D, Yang Z, Wang Q, Lin H, Zhang H, Hu Y, Liu D, Ye D, et al. Development of RelB-targeting small-molecule inhibitors of non-canonical NF-\u03baB signaling with antitumor efficacy. Mol Ther. 2025;33(4):1519\u20131534.","journal-title":"Mol Ther"},{"issue":"8","key":"e_1_3_4_351_1","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1021\/acs.jmedchem.3c02182","article-title":"Novel NF-\u03baB inhibitor-conjugated Pt (IV) prodrug to enable cancer therapy through ROS\/ER stress and mitochondrial dysfunction and overcome multidrug resistance","volume":"67","author":"Wang M","year":"2024","unstructured":"Wang M, Li G, Jiang G, Cai J, Liu Z, Huang R, Huang X, Wang H. Novel NF-\u03baB inhibitor-conjugated Pt (IV) prodrug to enable cancer therapy through ROS\/ER stress and mitochondrial dysfunction and overcome multidrug resistance. J Med Chem. 2024;67(8):6218\u20136237.","journal-title":"J Med Chem"},{"key":"e_1_3_4_352_1","doi-asserted-by":"crossref","first-page":"117898","DOI":"10.1016\/j.ejmech.2025.117898","article-title":"Novel 3, 4-dihydronaphthalen-1 (2H)-one derivatives promote apoptosis and inhibit migration of hepatocellularcarcinoma cells via inhibition of NF-\u03baB and MAPK signaling pathways","volume":"296","author":"Yu L","year":"2025","unstructured":"Yu L, Xia D-L, Chen Y, Miao Y-H, Xu R, Pan Y-X, Li Y-L, Li W-X, Hou Y, Liu Y-J, et al. Novel 3, 4-dihydronaphthalen-1 (2H)-one derivatives promote apoptosis and inhibit migration of hepatocellularcarcinoma cells via inhibition of NF-\u03baB and MAPK signaling pathways. Eur J Med Chem. 2025;296:117898.","journal-title":"Eur J Med Chem"},{"issue":"5","key":"e_1_3_4_353_1","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1021\/acs.jmedchem.4c02840","article-title":"Discovery of a novel EF24 Analogue-conjugated Pt (IV) complex as multi-target Pt (IV) prodrugs aims to enhance anticancer activity and overcome cisplatin resistance","volume":"68","author":"Wang M","year":"2025","unstructured":"Wang M, Li G, Xu N, Wang L, Cai J, Huang R, Yang Y, Chen G, Liu Z, Zhang Y, et al. Discovery of a novel EF24 Analogue-conjugated Pt (IV) complex as multi-target Pt (IV) prodrugs aims to enhance anticancer activity and overcome cisplatin resistance. J Med Chem. 2025;68(5):5597\u20135615.","journal-title":"J Med Chem"},{"issue":"15","key":"e_1_3_4_354_1","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1021\/acs.jmedchem.2c00922","article-title":"Discovery of hexahydrofuro [3, 2-b] furans as new kinase-selective and orally bioavailable JAK3 inhibitors for the treatment of leukemia harboring a JAK3 activating mutant","volume":"65","author":"Li S","year":"2022","unstructured":"Li S, Si H, Song X, Lei C, He X, Wang J, Liu Y, Zhou Y, Song J-G, Peng L, et al. Discovery of hexahydrofuro [3, 2-b] furans as new kinase-selective and orally bioavailable JAK3 inhibitors for the treatment of leukemia harboring a JAK3 activating mutant. J Med Chem. 2022;65(15):10674\u201310690.","journal-title":"J Med Chem"},{"issue":"37","key":"e_1_3_4_355_1","doi-asserted-by":"crossref","first-page":"33587","DOI":"10.1021\/acsomega.2c04769","article-title":"Discovery of JAK2\/3 inhibitors from quinoxalinone-containing compounds","volume":"7","author":"Sanachai K","year":"2022","unstructured":"Sanachai K, Mahalapbutr P, Tabtimmai L, Seetaha S, Kittikool T, Yotphan S, Choowongkomon K, Rungrotmongkol T. Discovery of JAK2\/3 inhibitors from quinoxalinone-containing compounds. ACS Omega. 2022;7(37):33587\u201333598.","journal-title":"ACS Omega"},{"key":"e_1_3_4_356_1","doi-asserted-by":"crossref","first-page":"113333","DOI":"10.1016\/j.ejmech.2021.113333","article-title":"Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors","volume":"216","author":"Gao D","year":"2021","unstructured":"Gao D, Jin N, Fu Y, Zhu Y, Wang Y, Wang T, Chen Y, Zhang M, Xiao Q, Huang M, et al. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors. Eur J Med Chem. 2021;216:113333.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"e_1_3_4_357_1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of novel pyrrolo [2, 3-d] pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors","volume":"65","author":"Liang X","year":"2022","unstructured":"Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, et al. Discovery of novel pyrrolo [2, 3-d] pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors. J Med Chem. 2022;65(2):1243\u20131264.","journal-title":"J Med Chem"},{"issue":"8","key":"e_1_3_4_358_1","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/acs.jmedchem.3c00036","article-title":"Exploration of janus kinase (JAK) and histone deacetylase (HDAC) bispecific inhibitors based on the moiety of fedratinib for treatment of both hematologic malignancies and solid cancers","volume":"66","author":"Qiu Q","year":"2023","unstructured":"Qiu Q, Chi F, Zhou D, Xie Z, Liu Y, Wu H, Yin Z, Shi W, Qian H. Exploration of janus kinase (JAK) and histone deacetylase (HDAC) bispecific inhibitors based on the moiety of fedratinib for treatment of both hematologic malignancies and solid cancers. J Med Chem. 2023;66(8):5753\u20135773.","journal-title":"J Med Chem"},{"issue":"11","key":"e_1_3_4_359_1","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1021\/acs.jmedchem.1c00136","article-title":"Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer","volume":"64","author":"Ren Y","year":"2021","unstructured":"Ren Y, Li S, Zhu R, Wan C, Song D, Zhu J, Cai G, Long S, Kong L, Yu W. Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer. J Med Chem. 2021;64(11):7468\u20137482.","journal-title":"J Med Chem"},{"issue":"20","key":"e_1_3_4_360_1","doi-asserted-by":"crossref","first-page":"14150","DOI":"10.1021\/acs.jmedchem.3c01242","article-title":"Discovery of novel fedratinib-based HDAC\/JAK\/BRD4 triple inhibitors with remarkable antitumor activity against triple negative breast cancer","volume":"66","author":"Zhao C","year":"2023","unstructured":"Zhao C, Zhang Y, Zhang J, Li S, Liu M, Geng Y, Liu F, Chai Q, Meng H, Li M, et al. Discovery of novel fedratinib-based HDAC\/JAK\/BRD4 triple inhibitors with remarkable antitumor activity against triple negative breast cancer. J Med Chem. 2023;66(20):14150\u201314174.","journal-title":"J Med Chem"},{"key":"e_1_3_4_361_1","doi-asserted-by":"crossref","first-page":"117377","DOI":"10.1016\/j.ejmech.2025.117377","article-title":"Discovery of naphthoquinone-furo-piperidone derivatives as dual targeting agents of STAT3 and NQO1 for the treatment of breast cancer","volume":"287","author":"Lou S","year":"2025","unstructured":"Lou S, Shen C, Ni H, Fan C, Zhu Z, Hu X, Zhao H, Cui S. Discovery of naphthoquinone-furo-piperidone derivatives as dual targeting agents of STAT3 and NQO1 for the treatment of breast cancer. Eur J Med Chem. 2025;287:117377.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_362_1","doi-asserted-by":"crossref","first-page":"118120","DOI":"10.1016\/j.ejmech.2025.118120","article-title":"The synthesis and evaluation of new N-(pyrazin-2-yl)-4-aminopyrimidine derivatives targeted EGFR and JAK","volume":"300","author":"Yao H","year":"2025","unstructured":"Yao H, Cao L, Ma EE, Yang K, Ren Y, Hou P, Yan M, Li X. The synthesis and evaluation of new N-(pyrazin-2-yl)-4-aminopyrimidine derivatives targeted EGFR and JAK. Eur J Med Chem. 2025;300:118120.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_363_1","doi-asserted-by":"crossref","first-page":"104096","DOI":"10.1016\/j.bioorg.2020.104096","article-title":"Discovery of novel aminophosphonate derivatives containing pyrazole moiety as potential selective COX-2 inhibitors","volume":"102","author":"Zhang B","year":"2020","unstructured":"Zhang B, Hu X-T, Zhou K-M, Yang Y-S, Zhu H-L. Discovery of novel aminophosphonate derivatives containing pyrazole moiety as potential selective COX-2 inhibitors. Bioorg Chem. 2020;102:104096.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_364_1","doi-asserted-by":"crossref","first-page":"104390","DOI":"10.1016\/j.bioorg.2020.104390","article-title":"Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates","volume":"105","author":"Zhang B","year":"2020","unstructured":"Zhang B, Hu X-T, Gu J, Yang Y-S, Duan Y-T, Zhu H-L. Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates. Bioorg Chem. 2020;105:104390.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_365_1","doi-asserted-by":"crossref","first-page":"108537","DOI":"10.1016\/j.bioorg.2025.108537","article-title":"Design and synthesis of new 1, 4-naphthoquinones appended sulfenylated thiazoles as cyclooxygenase II inhibitors: exploring the utility in the development of anticancer agents","volume":"161","author":"Rani P","year":"2025","unstructured":"Rani P, Ranolia A, Joshi G, Singh S, Kumar R, Wahajuddin M, Kumar P, Singh D, Sindhu J. Design and synthesis of new 1, 4-naphthoquinones appended sulfenylated thiazoles as cyclooxygenase II inhibitors: exploring the utility in the development of anticancer agents. Bioorg. Chem. 2025;161:108537.","journal-title":"Bioorg. Chem"},{"key":"e_1_3_4_366_1","doi-asserted-by":"crossref","first-page":"106428","DOI":"10.1016\/j.bioorg.2023.106428","article-title":"Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities","volume":"134","author":"Fadaly WA","year":"2023","unstructured":"Fadaly WA, Elshaier YA, Nemr MT, Abdellatif KR. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities. Bioorg Chem. 2023;134:106428.","journal-title":"Bioorg Chem"},{"issue":"32","key":"e_1_3_4_367_1","doi-asserted-by":"crossref","first-page":"29512","DOI":"10.1021\/acsomega.3c03256","article-title":"New thiazole carboxamide derivatives as COX inhibitors: design, synthesis, anticancer screening, in silico molecular docking, and ADME profile studies","volume":"8","author":"Hawash M","year":"2023","unstructured":"Hawash M, Jaradat N, Sabobeh R, Abualhasan M, Qaoud MT. New thiazole carboxamide derivatives as COX inhibitors: design, synthesis, anticancer screening, in silico molecular docking, and ADME profile studies. ACS Omega. 2023;8(32):29512\u201329526.","journal-title":"ACS Omega"},{"issue":"41","key":"e_1_3_4_368_1","doi-asserted-by":"crossref","first-page":"38597","DOI":"10.1021\/acsomega.3c05695","article-title":"Biological evaluation of xanthene and thioxanthene derivatives as antioxidant, anticancer, and COX inhibitors","volume":"8","author":"Abualhasan M","year":"2023","unstructured":"Abualhasan M, Hawash M, Aqel S, Al-Masri M, Mousa A, Issa L. Biological evaluation of xanthene and thioxanthene derivatives as antioxidant, anticancer, and COX inhibitors. ACS Omega. 2023;8(41):38597\u201338606.","journal-title":"ACS Omega"},{"key":"e_1_3_4_369_1","doi-asserted-by":"crossref","first-page":"113566","DOI":"10.1016\/j.ejmech.2021.113566","article-title":"New nimesulide derivatives with amide\/sulfonamide moieties: selective COX-2 inhibition and antitumor effects","volume":"221","author":"G\u00fcng\u00f6r T","year":"2021","unstructured":"G\u00fcng\u00f6r T, Ozleyen A, Y\u0131lmaz YB, Siyah P, Ay M, Durda\u011f\u0131 S, Tumer TB. New nimesulide derivatives with amide\/sulfonamide moieties: selective COX-2 inhibition and antitumor effects. Eur J Med Chem. 2021;221:113566.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_370_1","doi-asserted-by":"crossref","first-page":"115712","DOI":"10.1016\/j.ejmech.2023.115712","article-title":"Discovery and optimization of 2, 3-diaryl-1, 3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity","volume":"259","author":"Shawky AM","year":"2023","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Youssif BGM, Abdel-Fattah MM, Hersi F, El-Sherief HAM, Ibrahim NA, Gouda AM. Discovery and optimization of 2, 3-diaryl-1, 3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity. Eur J Med Chem. 2023;259:115712.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_371_1","doi-asserted-by":"crossref","first-page":"116397","DOI":"10.1016\/j.ejmech.2024.116397","article-title":"Exploration of isoxazole analogs: synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling","volume":"271","author":"Hawash M","year":"2024","unstructured":"Hawash M, Abdallah S, Abudayyak M, Melhem Y, Abu Shamat M, Aghbar M, \u00c7apan I, Abualhasan M, Kumar A, Kami\u0144ski M, et al. Exploration of isoxazole analogs: synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling. Eur J Med Chem. 2024;271:116397.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"e_1_3_4_372_1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1080\/14756366.2021.1956912","article-title":"Design and synthesis of novel quinazolinones conjugated ibuprofen, indole acetamide, or thioacetohydrazide as selective COX-2 inhibitors: anti-inflammatory, analgesic and anticancer activities","volume":"36","author":"Sakr A","year":"2021","unstructured":"Sakr A, Rezq S, Ibrahim SM, Soliman E, Baraka MM, Romero DG, Kothayer H. Design and synthesis of novel quinazolinones conjugated ibuprofen, indole acetamide, or thioacetohydrazide as selective COX-2 inhibitors: anti-inflammatory, analgesic and anticancer activities. J Enzyme Inhib Med Chem. 2021;36(1):1810\u20131828.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"e_1_3_4_373_1","doi-asserted-by":"crossref","first-page":"111780","DOI":"10.1016\/j.ejmech.2019.111780","article-title":"Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: design, synthesis and investigation of cytotoxicity and anti-inflammatory potency","volume":"185","author":"Shawky AM","year":"2020","unstructured":"Shawky AM, Abourehab MAS, Abdalla AN, Gouda AM. Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: design, synthesis and investigation of cytotoxicity and anti-inflammatory potency. Eur J Med Chem. 2020;185:111780.","journal-title":"Eur J Med Chem"},{"issue":"15","key":"e_1_3_4_374_1","doi-asserted-by":"crossref","first-page":"11570","DOI":"10.1021\/acs.jmedchem.1c00890","article-title":"Gut-restricted selective cyclooxygenase-2 (COX-2) inhibitors for chemoprevention of colorectal cancer","volume":"64","author":"Zhang Z","year":"2021","unstructured":"Zhang Z, Ghosh A, Connolly PJ, King P, Wilde T, Wang J, Dong Y, Li X, Liao D, Chen H, et al. Gut-restricted selective cyclooxygenase-2 (COX-2) inhibitors for chemoprevention of colorectal cancer. J Med Chem. 2021;64(15):11570\u201311596.","journal-title":"J Med Chem"},{"key":"e_1_3_4_375_1","doi-asserted-by":"crossref","first-page":"106273","DOI":"10.1016\/j.bioorg.2022.106273","article-title":"Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR\/Topo-1 inhibition","volume":"131","author":"Halim PA","year":"2023","unstructured":"Halim PA, Sharkawi SMZ, Labib MB. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR\/Topo-1 inhibition. Bioorg Chem. 2023;131:106273.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_376_1","doi-asserted-by":"crossref","first-page":"107403","DOI":"10.1016\/j.bioorg.2024.107403","article-title":"Discovery of novel pyrazole based urea\/thiourea derivatives as multiple targeting VEGFR-2, EGFR(WT), EGFR(T790M) tyrosine kinases and COX-2 inhibitors, with anti-cancer and anti-inflammatory activities","volume":"147","author":"Fadaly WAA","year":"2024","unstructured":"Fadaly WAA, Nemr MTM, Kahk NM. Discovery of novel pyrazole based urea\/thiourea derivatives as multiple targeting VEGFR-2, EGFR(WT), EGFR(T790M) tyrosine kinases and COX-2 inhibitors, with anti-cancer and anti-inflammatory activities. Bioorg Chem. 2024;147:107403.","journal-title":"Bioorg Chem"},{"issue":"2","key":"e_1_3_4_377_1","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/acs.jmedchem.5c02815","article-title":"Design, synthesis, and evaluation of organic and organometallic pyrazoline derivatives as selective dual COX-2\/5-LOX inhibitors and potential anticancer agents","volume":"69","author":"Navarrete E","year":"2026","unstructured":"Navarrete E, C\u00e1ceres MT, Morales P, Mu\u00f1oz-Osses M, Blacque O, Mesdom P, Cariou K, Godoy F, Gasser G, Flores E, et al. Design, synthesis, and evaluation of organic and organometallic pyrazoline derivatives as selective dual COX-2\/5-LOX inhibitors and potential anticancer agents. J Med Chem. 2026;69(2):1387\u20131402.","journal-title":"J Med Chem"},{"issue":"15","key":"e_1_3_4_378_1","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.1021\/acs.jmedchem.2c00635","article-title":"N-2-(phenylamino) benzamide derivatives as dual inhibitors of COX-2 and topo I deter gastrointestinal cancers via targeting inflammation and tumor progression","volume":"65","author":"Li J","year":"2022","unstructured":"Li J, Hu X, Zhang H, Peng Y, Li S, Xiong Y, Jiang W, Wang Z. N-2-(phenylamino) benzamide derivatives as dual inhibitors of COX-2 and topo I deter gastrointestinal cancers via targeting inflammation and tumor progression. J Med Chem. 2022;65(15):10481\u201310505.","journal-title":"J Med Chem"},{"issue":"51","key":"e_1_3_4_379_1","doi-asserted-by":"crossref","first-page":"63276","DOI":"10.1021\/acsomega.5c09752","article-title":"Design and synthesis of thiadiazole derivatives as dual EGFR\/COX-2 inhibitors with anticancer and anti-inflammatory activities","volume":"10","author":"Hidir A","year":"2025","unstructured":"Hidir A, Osmaniye D, Sa\u011flik \u00d6zkan BN, Levent S, Kaplancikli ZA, \u00d6zkay Y. Design and synthesis of thiadiazole derivatives as dual EGFR\/COX-2 inhibitors with anticancer and anti-inflammatory activities. ACS Omega. 2025;10(51):63276\u201363292.","journal-title":"ACS Omega"},{"key":"e_1_3_4_380_1","doi-asserted-by":"crossref","first-page":"105171","DOI":"10.1016\/j.bioorg.2021.105171","article-title":"Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes","volume":"115","author":"El-Miligy MMM","year":"2021","unstructured":"El-Miligy MMM, Al-Kubeisi AK, El-Zemity SR, Nassra RA, Abu-Serie MM, Hazzaa AA. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes. Bioorg Chem. 2021;115:105171.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_381_1","doi-asserted-by":"crossref","first-page":"109081","DOI":"10.1016\/j.bioorg.2025.109081","article-title":"Pioneering 1,3,5-triaryl pyrazolines as promising dual inhibitors of COX-2 and 15-LOX endowed with potent anticancer activity: design, synthesis, and in silico study","volume":"166","author":"Abdullah D","year":"2025","unstructured":"Abdullah D, Baraka MM, Elshanawani AA, El-Sabbagh OI, Salem IM. Pioneering 1,3,5-triaryl pyrazolines as promising dual inhibitors of COX-2 and 15-LOX endowed with potent anticancer activity: design, synthesis, and in silico study. Bioorg Chem. 2025;166:109081.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_382_1","doi-asserted-by":"crossref","first-page":"108563","DOI":"10.1016\/j.bioorg.2025.108563","article-title":"Design and synthesis of new pyrazole hybrids linked to oxime and nitrate moieties as COX-2, EGFR(L858R\/T790M) inhibitors and nitric oxide donors with dual anti-inflammatory\/anti-proliferative activities","volume":"161","author":"Fadaly WAA","year":"2025","unstructured":"Fadaly WAA, Nemr MTM, Abd El-Hameed AM, Mohamed FEA, Zidan TH. Design and synthesis of new pyrazole hybrids linked to oxime and nitrate moieties as COX-2, EGFR(L858R\/T790M) inhibitors and nitric oxide donors with dual anti-inflammatory\/anti-proliferative activities. Bioorg Chem. 2025;161:108563.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_383_1","doi-asserted-by":"crossref","first-page":"108962","DOI":"10.1016\/j.bioorg.2025.108962","article-title":"Indole-imidazolone derivatives as dual Mcl-1\/COX-2 inhibitors: design-oriented synthesis, molecular docking, and dynamics studies with potential anticancer and anti-inflammatory activities","volume":"165","author":"Lamie PF","year":"2025","unstructured":"Lamie PF, Halim PA, Sayed AM, Kahk NM, Abdelhakeem MM, Mohamed FEA. Indole-imidazolone derivatives as dual Mcl-1\/COX-2 inhibitors: design-oriented synthesis, molecular docking, and dynamics studies with potential anticancer and anti-inflammatory activities. Bioorg Chem. 2025;165:108962.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_384_1","doi-asserted-by":"crossref","first-page":"108247","DOI":"10.1016\/j.bioorg.2025.108247","article-title":"Design, synthesis, and molecular dynamics-driven evaluation of quinoline-sulfonamide derivatives as potent and selective EGFR inhibitors with promising anti-cancer efficacy and safety profiles","volume":"157","author":"Elkotamy MS","year":"2025","unstructured":"Elkotamy MS, Elgohary MK, Elkelesh IA, Alkabbani MA, Khaleel EF, Eldehna WM, Abdel-Aziz HA. Design, synthesis, and molecular dynamics-driven evaluation of quinoline-sulfonamide derivatives as potent and selective EGFR inhibitors with promising anti-cancer efficacy and safety profiles. Bioorg Chem. 2025;157:108247.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_385_1","doi-asserted-by":"crossref","first-page":"109444","DOI":"10.1016\/j.bioorg.2025.109444","article-title":"Pyrazole derivatives as dual COX-2\/EGFR inhibitors with anticancer potential: optimization of difenamizole Analogs","volume":"170","author":"Farag KO","year":"2026","unstructured":"Farag KO, Nour MS, Abdelhafez MM, Ibrahim NM, Abdel-Aziz HA, Fahim SH. Pyrazole derivatives as dual COX-2\/EGFR inhibitors with anticancer potential: optimization of difenamizole Analogs. Bioorg Chem. 2026;170:109444.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_386_1","doi-asserted-by":"crossref","first-page":"109162","DOI":"10.1016\/j.bioorg.2025.109162","article-title":"Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR\/VEGFR-2 inhibition","volume":"166","author":"Serag MI","year":"2025","unstructured":"Serag MI, Hamdi A, Nasr EE, Elnagar MR, Tawfik MM, El-Azab AS, Brogi S, Al-Suwaidan IA, Hefnawy M, Abdel-Aziz AA. Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR\/VEGFR-2 inhibition. Bioorg Chem. 2025;166:109162.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_387_1","doi-asserted-by":"crossref","first-page":"106171","DOI":"10.1016\/j.bioorg.2022.106171","article-title":"Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities","volume":"129","author":"Ahmed AHH","year":"2022","unstructured":"Ahmed AHH, Mohamed MFA, Allam RM, Nafady A, Mohamed SK, Gouda AE, Beshr EAM. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities. Bioorg Chem. 2022;129:106171.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_388_1","doi-asserted-by":"crossref","first-page":"109667","DOI":"10.1016\/j.bioorg.2026.109667","article-title":"Structure-guided discovery of 4-phenyl-5-p-tolyloxymethyl-4H-1,2,4-triazole thioethers as 15-lipoxygenase inhibitors using integrated in vitro, structure-activity relationship, in silico, cytotoxicity towards MCF-7 cell line, DNA docking and MD simulation methods","volume":"173","author":"Nawaz D","year":"2026","unstructured":"Nawaz D, Bashir B, Iqbal A, Momen A, Ashraf M, Ashok AK, Azhar A, Riaz N. Structure-guided discovery of 4-phenyl-5-p-tolyloxymethyl-4H-1,2,4-triazole thioethers as 15-lipoxygenase inhibitors using integrated in vitro, structure-activity relationship, in silico, cytotoxicity towards MCF-7 cell line, DNA docking and MD simulation methods. Bioorg Chem. 2026;173:109667.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_389_1","doi-asserted-by":"crossref","first-page":"112439","DOI":"10.1016\/j.ejmech.2020.112439","article-title":"Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases","volume":"200","author":"Elzahhar P. A.","year":"2020","unstructured":"Elzahhar, P. A.; Abd El Wahab, S. M.; Elagawany, M.; Daabees, H.; Belal, A. S. F.; El-Yazbi, A. F.; Eid, A. H.; Alaaeddine, R.; Hegazy, R. R.; Allam, R. M.; et al. Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases. Eur J Med Chem. 2020;200:112439. doi: :","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_390_1","doi-asserted-by":"crossref","first-page":"117402","DOI":"10.1016\/j.ejmech.2025.117402","article-title":"Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition","volume":"289","author":"Lauro G","year":"2025","unstructured":"Lauro G, Aliberti M, De Nisco M, Pedatella S, Pepe G, Basilicata MG, Chini MG, Fischer K, Hofstetter RK, Werz O, et al. Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition. Eur J Med Chem. 2025;289:117402.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_391_1","doi-asserted-by":"crossref","first-page":"113817","DOI":"10.1016\/j.ejmech.2021.113817","article-title":"N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: synthesis and biological evaluation","volume":"226","author":"Li J","year":"2021","unstructured":"Li J, Hu X, Luo T, Lu Y, Feng Y, Zhang H, Liu D, Fan X, Wang Y, Jiang L, et al. N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: synthesis and biological evaluation. Eur J Med Chem. 2021;226:113817.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_392_1","doi-asserted-by":"crossref","first-page":"113564","DOI":"10.1016\/j.ejmech.2021.113564","article-title":"Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma","volume":"222","author":"Fan X","year":"2021","unstructured":"Fan X, Li J, Long L, Shi T, Liu D, Tan W, Zhang H, Wu X, Lei X, Wang Z. Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma. Eur J Med Chem. 2021;222:113564.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"e_1_3_4_393_1","doi-asserted-by":"crossref","first-page":"118304","DOI":"10.1016\/j.ejmech.2025.118304","article-title":"Click-modifiable isatin hydrazones as COX-2, VEGFR-2, and carbonic anhydrase inhibitors: a multi-target approach to cancer therapy","volume":"302","author":"El-Attar MAZ","year":"2026","unstructured":"El-Attar MAZ, Afifi OS, Ismail A, Kamel YN, Yassin HA, Nomeir HM, Nematalla HA, Angeli A, Labib HF, Eldehna WM, et al. Click-modifiable isatin hydrazones as COX-2, VEGFR-2, and carbonic anhydrase inhibitors: a multi-target approach to cancer therapy. Eur J Med Chem. 2026;302(Pt 1):118304.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_394_1","doi-asserted-by":"crossref","first-page":"117340","DOI":"10.1016\/j.ejmech.2025.117340","article-title":"Optimization of pyrazole\/1,2,4-triazole as dual EGFR\/COX-2 inhibitors: design, synthesis, anticancer potential, apoptosis induction and cell cycle analysis","volume":"287","author":"Kahk NM","year":"2025","unstructured":"Kahk NM, Mohamed FEA, Abdelhakeem MM, Bakr RB. Optimization of pyrazole\/1,2,4-triazole as dual EGFR\/COX-2 inhibitors: design, synthesis, anticancer potential, apoptosis induction and cell cycle analysis. Eur J Med Chem. 2025;287:117340.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_395_1","doi-asserted-by":"crossref","first-page":"114560","DOI":"10.1016\/j.ejmech.2022.114560","article-title":"Discovery of dual inhibitors of topoisomerase I and cyclooxygenase-2 for colon cancer therapy","volume":"240","author":"Hu X","year":"2022","unstructured":"Hu X, Li J, Zhang H, Yu Q, Wang Y, Li X, Long L, Jiang W, Wang Z. Discovery of dual inhibitors of topoisomerase I and cyclooxygenase-2 for colon cancer therapy. Eur J Med Chem. 2022;240:114560.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_396_1","doi-asserted-by":"crossref","first-page":"115515","DOI":"10.1016\/j.ejmech.2023.115515","article-title":"Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs","volume":"257","author":"Liu X","year":"2023","unstructured":"Liu X, Wenisch D, Dahlke P, Jordan PM, Jakupec MA, Kowol CR, Liebing P, Werz O, Keppler BK, Weigand W. Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs. Eur J Med Chem. 2023;257:115515.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"e_1_3_4_397_1","doi-asserted-by":"crossref","first-page":"2290461","DOI":"10.1080\/14756366.2023.2290461","article-title":"New 1,2,3-triazole\/1,2,4-triazole hybrids linked to oxime moiety as nitric oxide donor selective COX-2, aromatase, B-RAF(V600E) and EGFR inhibitors celecoxib analogs: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis and molecular modeling study","volume":"38","author":"Fadaly WAA","year":"2023","unstructured":"Fadaly WAA, Nemr MTM, Zidan TH, Mohamed FEA, Abdelhakeem MM, Abu Jayab NN, Omar HA, Abdellatif KRA. New 1,2,3-triazole\/1,2,4-triazole hybrids linked to oxime moiety as nitric oxide donor selective COX-2, aromatase, B-RAF(V600E) and EGFR inhibitors celecoxib analogs: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis and molecular modeling study. J Enzyme Inhib Med Chem. 2023;38(1):2290461.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"e_1_3_4_398_1","doi-asserted-by":"crossref","first-page":"2281262","DOI":"10.1080\/14756366.2023.2281262","article-title":"New pyrazolyl-thiazolidinone\/thiazole derivatives as celecoxib\/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis, molecular modelling and ADME studies","volume":"38","author":"Fadaly WAA","year":"2023","unstructured":"Fadaly WAA, Zidan TH, Kahk NM, Mohamed FEA, Abdelhakeem MM, Khalil RG, Nemr MTM. New pyrazolyl-thiazolidinone\/thiazole derivatives as celecoxib\/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis, molecular modelling and ADME studies. J Enzyme Inhib Med Chem. 2023;38(1):2281262.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"e_1_3_4_399_1","doi-asserted-by":"crossref","first-page":"2199166","DOI":"10.1080\/14756366.2023.2199166","article-title":"Triple targeting of mutant EGFR(L858R\/T790M), COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation","volume":"38","author":"Kothayer H","year":"2023","unstructured":"Kothayer H, Rezq S, Abdelkhalek AS, Romero DG, Elbaramawi SS. Triple targeting of mutant EGFR(L858R\/T790M), COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation. J Enzyme Inhib Med Chem. 2023;38(1):2199166.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"7","key":"e_1_3_4_400_1","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1021\/acs.jmedchem.3c00175","article-title":"Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer","volume":"66","author":"Albanese V","year":"2023","unstructured":"Albanese V, Missiroli S, Perrone M, Fabbri M, Boncompagni C, Pacifico S, De Ventura T, Ciancetta A, Dondio G, Kricek F, et al. Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer. J Med Chem. 2023;66(7):5223\u20135241.","journal-title":"J Med Chem"},{"key":"e_1_3_4_401_1","doi-asserted-by":"crossref","first-page":"109429","DOI":"10.1016\/j.bioorg.2025.109429","article-title":"A Phenstatin-based indole-chalcone hybrid as novel anti-inflammatory agent targeting the NLRP3 Inflammasome: leads from computational and preclinical studies","volume":"170","author":"Meher RK","year":"2026","unstructured":"Meher RK, Maharana J, Kovvuri J, Kumar KN, Pradhan T, Kailaje V, Ingle A, Sen S, Barkume M, Patkar M, et al. A Phenstatin-based indole-chalcone hybrid as novel anti-inflammatory agent targeting the NLRP3 Inflammasome: leads from computational and preclinical studies. Bioorg Chem. 2026;170:109429.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_402_1","doi-asserted-by":"crossref","first-page":"118165","DOI":"10.1016\/j.ejmech.2025.118165","article-title":"Microwave-assisted one-pot green synthesis, ADMET profiling, DFT, and molecular docking of novel 3-cyano-2-pyridone derivatives as dual EGFR and cytokine (TNF-\u03b1, IL-6) inhibitors","volume":"300","author":"Lotfy EM","year":"2025","unstructured":"Lotfy EM, Bokhtia RM, Abdel Fattah HA, Seliem IA. Microwave-assisted one-pot green synthesis, ADMET profiling, DFT, and molecular docking of novel 3-cyano-2-pyridone derivatives as dual EGFR and cytokine (TNF-\u03b1, IL-6) inhibitors. Eur J Med Chem. 2025;300:118165.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_403_1","doi-asserted-by":"crossref","first-page":"118535","DOI":"10.1016\/j.ejmech.2025.118535","article-title":"Sinomenine derivative 1f suppresses glioblastoma through inducing both apoptosis mediated by intrinsic pathway and necroptosis mediated by TNF-\u03b1\/NF-\u03baB\/MAPK signaling pathway","volume":"304","author":"Jiang B","year":"2026","unstructured":"Jiang B, Xu F, Liu J, Li X, Cao W, Song H, Zhang S, Zhao Y, Li W, Yue Z, et al. Sinomenine derivative 1f suppresses glioblastoma through inducing both apoptosis mediated by intrinsic pathway and necroptosis mediated by TNF-\u03b1\/NF-\u03baB\/MAPK signaling pathway. Eur J Med Chem. 2026;304:118535.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_404_1","doi-asserted-by":"crossref","first-page":"117751","DOI":"10.1016\/j.ejmech.2025.117751","article-title":"Discovery and optimization of 2-pyridones as dual h-DHFR\/EGFR(TK) inhibitors with immunomodulatory potential; design, synthesis, anti-proliferative activity, and apoptosis inducer","volume":"294","author":"Ragab A","year":"2025","unstructured":"Ragab A, Raslan RR, Abusaif MS, Thabet HK, Ammar YA, Gohar NA. Discovery and optimization of 2-pyridones as dual h-DHFR\/EGFR(TK) inhibitors with immunomodulatory potential; design, synthesis, anti-proliferative activity, and apoptosis inducer. Eur J Med Chem. 2025;294:117751.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_405_1","doi-asserted-by":"crossref","first-page":"115566","DOI":"10.1016\/j.ejmech.2023.115566","article-title":"Design, synthesis, and evaluation of new anti-inflammatory natural products amide derivatives endowed with anti-blood cancer activity towards development of potential multifunctional agents against hematological cancers","volume":"258","author":"Hassan AHE","year":"2023","unstructured":"Hassan AHE, Kim HJ, Jung SJ, Jang SY, El-Sayed SM, Lee KT, Lee YS. Design, synthesis, and evaluation of new anti-inflammatory natural products amide derivatives endowed with anti-blood cancer activity towards development of potential multifunctional agents against hematological cancers. Eur J Med Chem. 2023;258:115566.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_406_1","doi-asserted-by":"crossref","first-page":"117005","DOI":"10.1016\/j.ejmech.2024.117005","article-title":"Design, synthesis, and cytotoxicity screening of novel pyrazolopyrimidines over renal cell carcinoma (UO-31 cells) as p38\u03b1 inhibitors, and apoptotic cells inducing activities","volume":"281","author":"Ewieda SY","year":"2025","unstructured":"Ewieda SY, Sonousi A, Kamal AM, Abdelhamid MK. Design, synthesis, and cytotoxicity screening of novel pyrazolopyrimidines over renal cell carcinoma (UO-31 cells) as p38\u03b1 inhibitors, and apoptotic cells inducing activities. Eur J Med Chem. 2025;281:117005.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_407_1","doi-asserted-by":"crossref","first-page":"114252","DOI":"10.1016\/j.ejmech.2022.114252","article-title":"Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors","volume":"234","author":"Nan G","year":"2022","unstructured":"Nan G, Huang L, Li Y, Yang Y, Yang Y, Li K, Lai F, Chen X, Xiao Z. Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors. Eur J Med Chem. 2022;234:114252.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_408_1","doi-asserted-by":"crossref","first-page":"112537","DOI":"10.1016\/j.ejmech.2020.112537","article-title":"Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity","volume":"205","author":"Li Z","year":"2020","unstructured":"Li Z, Wang X, Lin Y, Wang Y, Wu S, Xia K, Xu C, Ma H, Zheng J, Luo L, et al. Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity. Eur J Med Chem. 2020;205:112537.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_409_1","doi-asserted-by":"crossref","first-page":"112387","DOI":"10.1016\/j.ejmech.2020.112387","article-title":"Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists","volume":"204","author":"Xue D","year":"2020","unstructured":"Xue D, Chen W, Neamati N. Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists. Eur J Med Chem. 2020;204:112387.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_410_1","doi-asserted-by":"crossref","first-page":"117249","DOI":"10.1016\/j.ejmech.2025.117249","article-title":"Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance","volume":"285","author":"Li G","year":"2025","unstructured":"Li G, Wang M, Luo L, Tang D, Xu N, Huang R, Yang Y, Chen G, Liu Z, Wang H, et al. Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance. Eur J Med Chem. 2025;285:117249.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_411_1","doi-asserted-by":"crossref","first-page":"118072","DOI":"10.1016\/j.ejmech.2025.118072","article-title":"Development of potent glutathione transferase Omega-1 inhibitors with applications in inflammation and cancer therapy","volume":"299","author":"Xie Y","year":"2025","unstructured":"Xie Y, Nakano Y, Tummala P, Oakley AJ, Suwandi A, Cuellar ME, Strasser JM, Dahlin JL, Walters MA, Casarotto MG, et al. Development of potent glutathione transferase Omega-1 inhibitors with applications in inflammation and cancer therapy. Eur J Med Chem. 2025;299:118072.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_412_1","doi-asserted-by":"crossref","first-page":"108788","DOI":"10.1016\/j.bioorg.2025.108788","article-title":"N-substituted phthalimide-carboxylic acid hybrids as dual-targeted aldose reductase inhibitors: synthesis, mechanistic insights, and cancer-relevant profiling","volume":"163","author":"Zognjani B","year":"2025","unstructured":"Zognjani B, Nixha AR, Duran HE, Arslan M, Y\u0131ld\u0131ztekin G, Ece A, T\u00fcrke\u015f C. N-substituted phthalimide-carboxylic acid hybrids as dual-targeted aldose reductase inhibitors: synthesis, mechanistic insights, and cancer-relevant profiling. Bioorg Chem. 2025;163:108788.","journal-title":"Bioorg Chem"},{"issue":"5","key":"e_1_3_4_413_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","article-title":"From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage","volume":"15","author":"Giordano S","year":"2008","unstructured":"Giordano S, Petrelli A. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. CMC. 2008;15(5):422\u2013432.","journal-title":"CMC"},{"key":"e_1_3_4_414_1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: the next generation anticancer agents","volume":"143","author":"Raghavendra NM","year":"2018","unstructured":"Raghavendra NM, Pingili D, Kadasi S, Mettu A, Prasad S. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Chem. 2018;143:1277\u20131300.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"e_1_3_4_415_1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/ijms26030988","article-title":"Prodrugs in oncology: bioactivation and impact on therapeutic efficacy and toxicity","volume":"26","author":"Kurian R","year":"2025","unstructured":"Kurian R, Wang H. Prodrugs in oncology: bioactivation and impact on therapeutic efficacy and toxicity. Int J Mol Sci. 2025;26(3):988.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"e_1_3_4_416_1","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.3390\/ijms27072930","article-title":"Emerging CRISPR approaches for countering immune evasion: insight from recent studies","volume":"27","author":"Abubakar S","year":"2026","unstructured":"Abubakar S, Abdulsalam L, Fatty L, Kanwal R, Naeem M, Ahmad I. Emerging CRISPR approaches for countering immune evasion: insight from recent studies. Int J Mol Sci. 2026;27(7):2930.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"e_1_3_4_417_1","first-page":"e70389","article-title":"Gene and RNA editing: revolutionary approaches to treating diseases","volume":"6","author":"Li JM","year":"2025","unstructured":"Li JM, Huang J, Liao Y, Hu T, Wang CL, Zhang WZ, Huang CW. Gene and RNA editing: revolutionary approaches to treating diseases. MedComm (2020). 2025;6(10):e70389.","journal-title":"MedComm (2020)"},{"issue":"3","key":"e_1_3_4_418_1","doi-asserted-by":"crossref","first-page":"106077","DOI":"10.1016\/j.esmoop.2026.106077","article-title":"Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer","volume":"11","author":"Katayama Y","year":"2026","unstructured":"Katayama Y, Fukuda A, Inoue R, Kawachi H, Sawada R, Harada T, Yoshimura A, Okada A, Shiotsu S, Chihara Y, et al. Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer. ESMO Open. 2026;11(3):106077.","journal-title":"ESMO Open"},{"issue":"4","key":"e_1_3_4_419_1","doi-asserted-by":"crossref","first-page":"e71738","DOI":"10.1002\/cam4.71738","article-title":"Influence of gut microbiota on response to immune check point inhibitors in MASLD patients with HCC: unraveling the connection","volume":"15","author":"Elsheikh M","year":"2026","unstructured":"Elsheikh M, Ibrahim MA, Fares S, Bhongade M, Adhem K, Ramirez-Morales XI, Kaseb AO, Petrosino J, Hassan MM, Jalal PK. Influence of gut microbiota on response to immune check point inhibitors in MASLD patients with HCC: unraveling the connection. Cancer Med. 2026;15(4):e71738.","journal-title":"Cancer Med"},{"issue":"1","key":"e_1_3_4_420_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s42003-025-09310-2","article-title":"Single-cell and spatial transcriptomic profiling reveals distinct tumor microenvironment dynamics in cervical adenocarcinoma and squamous cell carcinoma","volume":"9","author":"Wu Y","year":"2025","unstructured":"Wu Y, Wei B, Wei Z, Wang H, Liu Y, Xu D, Li X, Guo L, Lu H, Shang H. Single-cell and spatial transcriptomic profiling reveals distinct tumor microenvironment dynamics in cervical adenocarcinoma and squamous cell carcinoma. Commun Biol. 2025;9(1):46.","journal-title":"Commun Biol"},{"key":"e_1_3_4_421_1","doi-asserted-by":"crossref","first-page":"1732340","DOI":"10.3389\/fmolb.2025.1732340","article-title":"Bridging ancient wisdom and modern technology: an AI and multi-omics framework for three causes tailored treatment in personalized medicine","volume":"12","author":"Diao X","year":"2025","unstructured":"Diao X, Zhang H, Wang S, Zhang Q, Wang Z. Bridging ancient wisdom and modern technology: an AI and multi-omics framework for three causes tailored treatment in personalized medicine. Front Mol Biosci. 2025;12:1732340.","journal-title":"Front Mol Biosci"},{"issue":"11","key":"e_1_3_4_422_1","doi-asserted-by":"crossref","first-page":"181321","DOI":"10.1098\/rsos.181321","article-title":"Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining","volume":"5","author":"Liu TP","year":"2018","unstructured":"Liu TP, Hsieh YY, Chou CJ, Yang PM. Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining. R Soc Open Sci. 2018;5(11):181321.","journal-title":"R Soc Open Sci"},{"issue":"1","key":"e_1_3_4_423_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang B","year":"2024","unstructured":"Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, Wang K, Xu J, Cheng Y, Gao X. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9(1):200.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_4_424_1","doi-asserted-by":"crossref","first-page":"e18960","DOI":"10.1002\/advs.202518960","article-title":"Combination immunotherapy as a promising strategy to overcome immunotherapy resistance: from emergence to next-generation approaches","author":"Pandey A","year":"2026","unstructured":"Pandey A, Rai SK, Ma L, Higa L, Khadka V, Yang H, Deng Y. Combination immunotherapy as a promising strategy to overcome immunotherapy resistance: from emergence to next-generation approaches. Adv Sci (Weinh). 2026:e18960.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"e_1_3_4_425_1","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1093\/carcin\/bgv038","article-title":"Environmental immune disruptors, inflammation and cancer risk","volume":"36","author":"Thompson PA","year":"2015","unstructured":"Thompson PA, Khatami M, Baglole CJ, Sun J, Harris SA, Moon EY, Al-Mulla F, Al-Temaimi R, Brown DG, Colacci A, et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015;36 (Suppl 1)1:S232\u2013S253.","journal-title":"Carcinogenesis"},{"key":"e_1_3_4_426_1","doi-asserted-by":"crossref","first-page":"100297","DOI":"10.1016\/j.jlb.2025.100297","article-title":"Enhancing detection and monitoring of circulating tumor cells: integrative approaches in liquid biopsy advances","volume":"8","author":"Velpula T","year":"2025","unstructured":"Velpula T, Buddolla V. Enhancing detection and monitoring of circulating tumor cells: integrative approaches in liquid biopsy advances. J Liq Biopsy. 2025;8:100297.","journal-title":"J Liq Biopsy"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2689287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14756366.2026.2689287","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2689287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:34:45Z","timestamp":1782480885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2689287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":425,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2689287"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2689287","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2689287"}}